<div id="displayContant">
<br><div class="long-title">
<span>ZEPATIER</span><span> (
					elbasvir and grazoprevir
				)</span>
</div>
<br><div class="section"><div id="ZEPATIER_collapsableElement_48780-1" style="margin-left:68px; margin-top: 20px;" class="collapseElement"><div class="descriptionText"></div></div></div>
<div class="section">
<div id="nonCollapsableElement_34067-9">
<div class="drugSubheadings">
<span id="ZEPATIER_34067-9" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>1 INDICATIONS AND USAGE</div>
<div id="ZEPATIER_previewText_34067-9" class="previewText">
                  ZEPATIER™ is indicated with or without ribavirin for the trea
                        ZEPATIER is a fixed-dose combination product containing<span>...</span>
</div>
</div>
<div id="ZEPATIER_collapsableElement_34067-9" style="margin-left:68px; margin-top: 20px;" class="collapseElement"><div class="descriptionText">
<text>
                  <p>ZEPATIER™ is indicated with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotypes 1 or 4 infection in adults.</p>
               </text><text>
                        <p>ZEPATIER is a fixed-dose combination product containing elbasvir, a hepatitis C virus (HCV) NS5A inhibitor, and grazoprevir, an HCV NS3/4A protease inhibitor, and is indicated with or without ribavirin for treatment of chronic HCV genotypes 1 or 4 infection in adults. (<a href="#S1">1</a>)</p>
                     </text>
</div></div>
</div>
<div class="section">
<div id="nonCollapsableElement_34068-7">
<div class="drugSubheadings">
<span id="ZEPATIER_34068-7" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>2 DOSAGE AND ADMINISTRATION</div>
<div id="ZEPATIER_previewText_34068-7" class="previewText">
                        
                           Testing prior to initiation<span>...</span>
</div>
</div>
<div id="ZEPATIER_collapsableElement_34068-7" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText"><text>
                        <ul ultype="unordered">
                           <li>Testing prior to initiation: 									<ul ultype="unordered" stylecode="disc">
                                 <li>Genotype 1a: Testing for the presence of virus with NS5A resistance-associated polymorphisms is recommended. (<a href="#S2.1">2.1</a>)</li>
                                 <li>Obtain hepatic laboratory testing. (<a href="#S2.1">2.1</a>)</li>
                              </ul>
                           </li>
                           <li>Recommended dosage: One tablet taken orally once daily with or without food. (<a href="#S2.2">2.2</a>)</li>
                        </ul>
                        <table width="100%">
                           <caption>Dosage Regimens and Durations for ZEPATIER in Patients with Genotype 1 or 4 HCV with or without Cirrhosis</caption>
                           <colgroup><col width="50%" align="center" valign="top">
                           <col width="25%" align="center" valign="bottom">
                           <col width="25%" align="center" valign="bottom">
                           </colgroup><thead>
                              <tr>
                                 <th stylecode="Lrule Rrule" valign="bottom">Patient Population</th>
                                 <th stylecode="Rrule">Treatment</th>
                                 <th stylecode="Rrule">Duration</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">Genotype 1a: <br>Treatment-naïve or PegIFN/RBV-experienced<footnote id="foot1">Peginterferon alfa + ribavirin.</footnote>&nbsp;<content stylecode="underline">without</content> baseline NS5A polymorphisms<footnote id="foot2">Polymorphisms at amino acid positions 28, 30, 31, or 93.</footnote>
                                 </td>
                                 <td stylecode="Rrule">ZEPATIER</td>
                                 <td stylecode="Rrule">12 weeks</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">Genotype 1a: <br>Treatment-naïve or PegIFN/RBV-experienced<footnoteref idref="foot1"></footnoteref>&nbsp;<content stylecode="underline">with</content> baseline NS5A polymorphisms<footnoteref idref="foot2"></footnoteref>
                                 </td>
                                 <td stylecode="Rrule">ZEPATIER + ribavirin</td>
                                 <td stylecode="Rrule">16 weeks</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">Genotype 1b: <br>Treatment-naïve or PegIFN/RBV-experienced<footnoteref idref="foot1"></footnoteref>
                                 </td>
                                 <td stylecode="Rrule">ZEPATIER</td>
                                 <td stylecode="Rrule">12 weeks</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">Genotype 1a or 1b: PegIFN/RBV/PI-experienced<footnote>Peginterferon alfa + ribavirin + HCV NS3/4A protease inhibitor.</footnote>
                                 </td>
                                 <td stylecode="Rrule" valign="top">ZEPATIER + ribavirin</td>
                                 <td stylecode="Rrule">12 weeks</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">Genotype 4: <br>Treatment-naïve</td>
                                 <td stylecode="Rrule">ZEPATIER</td>
                                 <td stylecode="Rrule">12 weeks</td>
                              </tr>
                              <tr>
                                 <td stylecode="Lrule Rrule">Genotype 4: <br>PegIFN/RBV-experienced<footnoteref idref="foot1"></footnoteref>
                                 </td>
                                 <td stylecode="Rrule" valign="top">ZEPATIER + ribavirin</td>
                                 <td stylecode="Rrule">16 weeks</td>
                              </tr>
                           </tbody>
                        </table>
                        <ul ultype="unordered">
                           <li>HCV/HIV-1 co-infection: Follow the dosage recommendations in the table above. (<a href="#S2.2">2.2</a>)</li>
                           <li>Renal Impairment, including hemodialysis: No dosage adjustment of ZEPATIER is recommended. Refer to ribavirin prescribing information for ribavirin dosing and dosage modifications. (<a href="#S2.3">2.3</a>)</li>
                        </ul>
                     </text></div>
<span id="ZEPATIER_collapsableElement_2_1" class="safetySubheading">2.1	Testing Prior to the Initiation of Therapy </span><div id="42229-5" class="safetySubdescription"></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">NS5A Resistance Testing in HCV Genotype 1a-Infected Patients</content>
                              </p>
                              <p>Testing patients with HCV genotype 1a infection for the presence of virus with NS5A resistance-associated polymorphisms is recommended prior to initiation of treatment with ZEPATIER to determine dosage regimen and duration <content stylecode="italics">[see <a href="#S2.2">Dosage and Administration (2.2)</a>], <a href="#t1">Table 1</a>
                                 </content>. In subjects receiving ZEPATIER for 12 weeks, sustained virologic response (SVR12) rates were lower in genotype 1a-infected patients with one or more baseline NS5A resistance-associated polymorphisms at amino acid positions 28, 30, 31, or 93 <content stylecode="italics">[see <a href="#S12.4">Microbiology (12.4)</a>], <a href="#t11">Table 11</a>
                                 </content>. </p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Hepatic Laboratory Testing</content>
                              </p>
                              <p>Obtain hepatic laboratory testing prior to and during treatment with ZEPATIER <content stylecode="italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>].</content>
                              </p>
                           </text></div>
<span id="ZEPATIER_collapsableElement_2_2" class="safetySubheading">2.2	Recommended Dosage in Adults</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>ZEPATIER is a two-drug, fixed-dose combination product containing 50 mg of elbasvir and 100 mg of grazoprevir in a single tablet. The recommended dosage of ZEPATIER is one tablet taken orally once daily with or without food <content stylecode="italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</content>. ZEPATIER is used in combination with ribavirin in certain patient populations (see <a href="#t1">Table 1</a>). When administered with ZEPATIER, the recommended dosage of ribavirin in patients without renal impairment is weight-based administered in two divided doses with food. For further information on ribavirin dosing and dosage modifications, refer to the ribavirin prescribing information.</p>
                     </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Treatment Regimen and Duration of Therapy</content>
                              </p>
                              <p>Relapse rates are affected by baseline host and viral factors and differ between treatment regimens and durations for certain subgroups <content stylecode="italics">[see <a href="#S14">Clinical Studies (14)</a>].</content>
                              </p>
                              <p>
                                 <a href="#t1">Table 1</a> below provides the recommended ZEPATIER treatment regimen and duration based on the patient population and genotype in HCV mono-infected and HCV/HIV-1 co-infected patients with or without cirrhosis and with or without renal impairment including patients receiving hemodialysis. </p>
                              <table width="90%" id="t1">
                                 <caption>Table 1: Recommended Dosage Regimens and Durations for ZEPATIER for Treatment of HCV Genotype 1 or 4 in Patients with or without Cirrhosis</caption>
                                 <colgroup><col width="50%" align="left" valign="top">
                                 <col width="25%" align="center" valign="top">
                                 <col width="25%" align="center" valign="top">
                                 </colgroup><thead>
                                    <tr>
                                       <th stylecode="Lrule Rrule" valign="bottom" align="center">Patient Population</th>
                                       <th stylecode="Rrule" valign="bottom">Treatment</th>
                                       <th stylecode="Rrule" valign="bottom">Duration</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Genotype 1a: Treatment-naïve or PegIFN/RBV-experienced<footnote id="t1f1">Patients who have failed treatment with peginterferon alfa (PegIFN) + ribavirin (RBV).</footnote>&nbsp;<content stylecode="underline">without</content> baseline NS5A polymorphisms<footnote id="t1f2">NS5A resistance-associated polymorphisms at amino acid positions 28, 30, 31, or 93. See <a href="#S2.1">section 2.1</a> Testing prior to the initiation of therapy, subsection NS5A resistance testing in HCV genotype 1a-infected patients.</footnote>
                                       </td>
                                       <td stylecode="Rrule">ZEPATIER</td>
                                       <td stylecode="Rrule">12 weeks</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Genotype 1a: Treatment-naïve or PegIFN/RBV-experienced<footnoteref idref="t1f1"></footnoteref>&nbsp;<content stylecode="underline">with</content> baseline NS5A polymorphisms<footnoteref idref="t1f2"></footnoteref>
                                       </td>
                                       <td stylecode="Rrule">ZEPATIER + RBV<footnote id="t1f3">For patients with CrCl greater than 50 mL per minute, the recommended dosage of ribavirin is weight-based (less than 66 kg = 800 mg per day, 66 to 80 kg = 1000 mg per day, 81 to 105 kg = 1200 mg per day, greater than 105 kg = 1400 mg per day) administered in two divided doses with food. For patients with CrCl less than or equal to 50 mL per minute, including patients receiving hemodialysis, refer to the ribavirin tablet prescribing information for the correct ribavirin dosage.</footnote>
                                       </td>
                                       <td stylecode="Rrule">16 weeks</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Genotype 1b: Treatment-naïve or PegIFN/RBV-experienced<footnoteref idref="t1f1"></footnoteref>
                                       </td>
                                       <td stylecode="Rrule">ZEPATIER</td>
                                       <td stylecode="Rrule">12 weeks</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Genotype 1a<footnote>The optimal ZEPATIER-based treatment regimen and duration of therapy for PegIFN/RBV/PI-experienced genotype 1a-infected patients with one or more baseline NS5A resistance-associated polymorphisms at positions 28, 30, 31, and 93 has not been established.</footnote> or 1b: PegIFN/RBV/PI-experienced<footnote>Patients who have failed treatment with PegIFN + RBV + HCV NS3/4A protease inhibitor (PI): boceprevir, simeprevir, or telaprevir.</footnote>
                                       </td>
                                       <td stylecode="Rrule">ZEPATIER + RBV<footnoteref idref="t1f3"></footnoteref>
                                       </td>
                                       <td stylecode="Rrule">12 weeks</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Genotype 4: Treatment-Naïve</td>
                                       <td stylecode="Rrule">ZEPATIER</td>
                                       <td stylecode="Rrule">12 weeks</td>
                                    </tr>
                                    <tr>
                                       <td stylecode="Lrule Rrule">Genotype 4: PegIFN/RBV-experienced<footnoteref idref="t1f1"></footnoteref>
                                       </td>
                                       <td stylecode="Rrule">ZEPATIER + RBV<footnoteref idref="t1f3"></footnoteref>
                                       </td>
                                       <td stylecode="Rrule">16 weeks</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text></div>
<span id="ZEPATIER_collapsableElement_2_3" class="safetySubheading">2.3	Renal Impairment </span><div id="42229-5" class="safetySubdescription"><text>
                        <p>No dosage adjustment of ZEPATIER is recommended in patients with any degree of renal impairment including patients on hemodialysis. Administer ZEPATIER with or without ribavirin according to the recommendations in <a href="#t1">Table 1</a>
                           <content stylecode="italics">[see <a href="#S8.8">Use in Specific Populations (8.8)</a> and <a href="#S14.4">Clinical Studies (14.4)</a>]</content>. Refer to the ribavirin tablet prescribing information for the correct ribavirin dosage for patients with CrCl less than or equal to 50 mL per minute. </p>
                     </text></div>
<span id="ZEPATIER_collapsableElement_2_4" class="safetySubheading">2.4	Hepatic Impairment </span><div id="42229-5" class="safetySubdescription"><text>
                        <p>No dosage adjustment of ZEPATIER is recommended in patients with mild hepatic impairment (Child-Pugh A). ZEPATIER is contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh B or C) <content stylecode="italics">[see <a href="#S4">Contraindications (4)</a>, <a href="#S8.9">Use in Specific Populations (8.9)</a>, and <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</content>
                        </p>
                     </text></div>
</div>
</div>
<div class="section">
<div id="nonCollapsableElement_43678-2">
<div class="drugSubheadings">
<span id="ZEPATIER_43678-2" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>3 DOSAGE FORMS AND STRENGTHS</div>
<div id="ZEPATIER_previewText_43678-2" class="previewText">
                  ZEPATIER is available as a beige-colored, oval-shaped, film-c
                        
                           Tablets: 50 mg elbasvir and<span>...</span>
</div>
</div>
<div id="ZEPATIER_collapsableElement_43678-2" style="margin-left:68px; margin-top: 20px;" class="collapseElement"><div class="descriptionText">
<text>
                  <p>ZEPATIER is available as a beige-colored, oval-shaped, film-coated tablet debossed with "770" on one side and plain on the other. Each tablet contains 50 mg elbasvir and 100 mg grazoprevir.</p>
               </text><text>
                        <ul ultype="unordered">
                           <li>Tablets: 50 mg elbasvir and 100 mg grazoprevir (<a href="#S3">3</a>)</li>
                        </ul>
                     </text>
</div></div>
</div>
<div class="section">
<div id="nonCollapsableElement_34070-3">
<div class="drugSubheadings">
<span id="ZEPATIER_34070-3" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>4 CONTRAINDICATIONS</div>
<div id="ZEPATIER_previewText_34070-3" class="previewText">
                  
                     ZEPATIER is contraindicated in patients
                        
                           Patients with moderate or s<span>...</span>
</div>
</div>
<div id="ZEPATIER_collapsableElement_34070-3" style="margin-left:68px; margin-top: 20px;" class="collapseElement"><div class="descriptionText">
<text>
                  <ul ultype="unordered">
                     <li>ZEPATIER is contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh B or C) due to the expected significantly increased grazoprevir plasma concentration and the increased risk of alanine aminotransferase (ALT) elevations <content stylecode="italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>, <a href="#S8.9">Use in Specific Populations (8.9)</a>, and <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</content>.</li>
                     <li>ZEPATIER is contraindicated with organic anion transporting polypeptides 1B1/3 (OATP1B1/3) inhibitors, strong inducers of cytochrome P450 3A (CYP3A), and efavirenz <content stylecode="italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>, <a href="#S7">Drug Interactions (7)</a>, and <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</content>.</li>
                     <li>If ZEPATIER is administered with ribavirin, the contraindications to ribavirin also apply to this combination regimen. Refer to the ribavirin prescribing information for a ul of contraindications for ribavirin.</li>
                  </ul>
                  <p>
                     <a href="#t2">Table 2</a> uls drugs that are contraindicated with ZEPATIER.</p>
                  <table width="90%" id="t2">
                     <caption>Table 2: Drugs that are Contraindicated with ZEPATIER</caption>
                     <colgroup><col width="25%" align="left" valign="top">
                     <col width="30%" align="left" valign="top">
                     <col width="45%" align="left" valign="top">
                     </colgroup><thead>
                        <tr>
                           <th stylecode="Rrule Lrule" align="center" valign="middle">Drug Class</th>
                           <th stylecode="Rrule">Drug(s) within Class that are Contraindicated</th>
                           <th stylecode="Rrule" align="center" valign="middle">Clinical Comment<footnote>This table is not a comprehensive ul of all drugs that inhibit OATP1B1/3 or strongly induce CYP3A.</footnote>
                           </th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr stylecode="Botrule">
                           <td stylecode="Rrule Lrule">Anticonvulsants</td>
                           <td stylecode="Rrule">Phenytoin<br>Carbamazepine </td>
                           <td stylecode="Rrule">May lead to loss of virologic response to ZEPATIER due to significant decreases in elbasvir and grazoprevir plasma concentrations caused by strong CYP3A induction.</td>
                        </tr>
                        <tr stylecode="Botrule">
                           <td stylecode="Rrule Lrule">Antimycobacterials</td>
                           <td stylecode="Rrule">Rifampin</td>
                           <td stylecode="Rrule">May lead to loss of virologic response to ZEPATIER due to significant decreases in elbasvir and grazoprevir plasma concentrations caused by strong CYP3A induction.</td>
                        </tr>
                        <tr stylecode="Botrule">
                           <td stylecode="Rrule Lrule">Herbal Products</td>
                           <td stylecode="Rrule">St. John's Wort (Hypericum perforatum)</td>
                           <td stylecode="Rrule">May lead to loss of virologic response to ZEPATIER due to significant decreases in elbasvir and grazoprevir plasma concentrations caused by strong CYP3A induction.</td>
                        </tr>
                        <tr stylecode="Botrule">
                           <td stylecode="Rrule Lrule">HIV Medications</td>
                           <td stylecode="Rrule">Efavirenz<footnote>Efavirenz is included as a strong CYP3A inducer in this table, since co-administration reduced grazoprevir exposure by ≥80% <content stylecode="italics">[see <a href="#t8">Table 8</a>]</content>.</footnote>
                           </td>
                           <td stylecode="Rrule">May lead to loss of virologic response to ZEPATIER due to significant decreases in elbasvir and grazoprevir plasma concentrations caused by CYP3A induction.</td>
                        </tr>
                        <tr stylecode="Botrule">
                           <td stylecode="Rrule Lrule">HIV Medications</td>
                           <td stylecode="Rrule">Atazanavir<br>Darunavir<br>Lopinavir<br>Saquinavir<br>Tipranavir</td>
                           <td stylecode="Rrule">May increase the risk of ALT elevations due to a significant increase in grazoprevir plasma concentrations caused by OATP1B1/3 inhibition.</td>
                        </tr>
                        <tr>
                           <td stylecode="Rrule Lrule">Immunosuppressants</td>
                           <td stylecode="Rrule">Cyclosporine</td>
                           <td stylecode="Rrule">May increase the risk of ALT elevations due to a significant increase in grazoprevir plasma concentrations caused by OATP1B1/3 inhibition.</td>
                        </tr>
                     </tbody>
                  </table>
               </text><text>
                        <ul ultype="unordered">
                           <li>Patients with moderate or severe hepatic impairment (Child-Pugh B or C). (<a href="#S4">4</a>)</li>
                           <li>OATP1B1/3 inhibitors, strong CYP3A inducers, and efavirenz. (<a href="#S4">4</a>) </li>
                           <li>If ZEPATIER is administered with ribavirin, the contraindications to ribavirin also apply. (<a href="#S4">4</a>)</li>
                        </ul>
                     </text>
</div></div>
</div>
<div class="section">
<div id="nonCollapsableElement_43685-7">
<div class="drugSubheadings">
<span id="ZEPATIER_43685-7" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>5 WARNINGS AND PRECAUTIONS</div>
<div id="ZEPATIER_previewText_43685-7" class="previewText">
                        
                           ALT elevations: Perform hep<span>...</span>
</div>
</div>
<div id="ZEPATIER_collapsableElement_43685-7" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText"><text>
                        <ul ultype="unordered">
                           <li>ALT elevations: Perform hepatic laboratory testing prior to therapy, at treatment week 8, and as clinically indicated. For patients receiving 16 weeks of therapy, perform additional hepatic laboratory testing at treatment week 12. For ALT elevations on ZEPATIER, follow recommendations in full prescribing information. (<a href="#S5.1">5.1</a>) </li>
                           <li>Risk associated with ribavirin combination treatment: If ZEPATIER is administered with ribavirin, the warnings and precautions for ribavirin also apply. (<a href="#S5.2">5.2</a>)</li>
                        </ul>
                     </text></div>
<span id="ZEPATIER_collapsableElement_5_1" class="safetySubheading">5.1	Increased Risk of ALT Elevations</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>During clinical trials with ZEPATIER with or without ribavirin, 1% of subjects experienced elevations of ALT from normal levels to greater than 5 times the upper limit of normal (ULN), generally at or after treatment week 8. ALT elevations were typically asymptomatic and most resolved with ongoing or completion of therapy. Higher rates of late ALT elevations occurred in the following subpopulations: female sex (2% [10/608]), Asian race (2% [4/164]), and age 65 years or older (2% [3/177]) <content stylecode="italics">[see <a href="#S6.1">Adverse Reactions (6.1)</a>]</content>. </p>
                        <p>Hepatic laboratory testing should be performed prior to therapy, at treatment week 8, and as clinically indicated. For patients receiving 16 weeks of therapy, additional hepatic laboratory testing should be performed at treatment week 12.</p>
                        <ul ultype="unordered">
                           <li>Patients should be instructed to consult their healthcare professional without delay if they have onset of fatigue, weakness, lack of appetite, nausea and vomiting, jaundice, or discolored feces.</li>
                           <li>Consider discontinuing ZEPATIER if ALT levels remain persistently greater than 10 times the ULN.</li>
                           <li>Discontinue ZEPATIER if ALT elevation is accompanied by signs or symptoms of liver inflammation or increasing conjugated bilirubin, alkaline phosphatase, or INR.</li>
                        </ul>
                     </text></div>
<span id="ZEPATIER_collapsableElement_5_2" class="safetySubheading">5.2	Risks Associated with Ribavirin Combination Treatment</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>If ZEPATIER is administered with ribavirin, the warnings and precautions for ribavirin, including the pregnancy avoidance warning, also apply to this combination regimen. Refer to the ribavirin prescribing information for a full ul of warnings and precautions for ribavirin <content stylecode="italics">[see <a href="#S2.2">Dosage and Administration (2.2)</a>]</content>.</p>
                     </text></div>
<span id="ZEPATIER_collapsableElement_5_3" class="safetySubheading">5.3	Risk of Adverse Reactions or Reduced Therapeutic Effect Due to Drug Interactions</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>The concomitant use of ZEPATIER and certain drugs may result in known or potentially significant drug interactions, some of which may lead to:</p>
                        <ul ultype="unordered">
                           <li>Possible clinically significant adverse reactions from greater exposure of concomitant drugs or components of ZEPATIER.</li>
                           <li>Significant decrease of elbasvir and grazoprevir plasma concentrations which may lead to reduced therapeutic effect of ZEPATIER and possible development of resistance.</li>
                        </ul>
                        <p>See <a href="#t2">Tables 2</a> and <a href="#t6">6</a> for steps to prevent or manage these known or potentially significant drug interactions, including dosing recommendations <content stylecode="italics">[see <a href="#S4">Contraindications (4)</a> and <a href="#S7.2">Drug Interactions (7.2)</a>]</content>. </p>
                     </text></div>
</div>
</div>
<div class="section">
<div id="nonCollapsableElement_34084-4">
<div class="drugSubheadings">
<span id="ZEPATIER_34084-4" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>6 ADVERSE REACTIONS</div>
<div id="ZEPATIER_previewText_34084-4" class="previewText">
                  The following adverse reaction is described below and elsewhe
                        In subjects receiving ZEPATIER for 12 weeks, the most c<span>...</span>
</div>
</div>
<div id="ZEPATIER_collapsableElement_34084-4" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText">
<text>
                  <p>The following adverse reaction is described below and elsewhere in the labeling: </p>
                  <ul ultype="unordered">
                     <li>Increased Risk of ALT Elevations <content stylecode="italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>].</content>
                     </li>
                  </ul>
               </text><text>
                        <p>In subjects receiving ZEPATIER for 12 weeks, the most commonly reported adverse reactions of all intensity (greater than or equal to 5% in placebo-controlled trials) were fatigue, headache, and nausea. In subjects receiving ZEPATIER with ribavirin for 16 weeks, the most commonly reported adverse reactions of moderate or severe intensity (greater than or equal to 5%) were anemia and headache. (<a href="#S6.1">6.1</a>)</p>
                        <br>
                        <p>
                           <content stylecode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc., at 1-877-888-4231 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </p>
                     </text>
</div>
<span id="ZEPATIER_collapsableElement_6_1" class="safetySubheading">6.1	Clinical Trials Experience</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
                        <p>If ZEPATIER is administered with ribavirin, refer to the prescribing information for ribavirin for a description of ribavirin-associated adverse reactions. </p>
                        <p>The safety of ZEPATIER was assessed based on 2 placebo-controlled trials and 7 uncontrolled Phase 2 and 3 clinical trials in approximately 1700 subjects with chronic hepatitis C virus infection with compensated liver disease (with or without cirrhosis) <content stylecode="italics">[see <a href="#S14">Clinical Studies (14)</a>]</content>. </p>
                     </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Adverse Reactions with ZEPATIER in Treatment-Naïve Subjects</content>
                              </p>
                              <p>C-EDGE TN was a Phase 3 randomized, double-blind, placebo-controlled trial in 421 treatment-naïve (TN) subjects with HCV infection who received ZEPATIER or placebo one tablet once daily for 12 weeks. Adverse reactions (all intensity) occurring in C-EDGE TN in at least 5% of subjects treated with ZEPATIER for 12 weeks are presented in <a href="#t3">Table 3</a>. In subjects treated with ZEPATIER who reported an adverse reaction, 73% had adverse reactions of mild severity. The type and severity of adverse reactions in subjects with compensated cirrhosis were comparable to those seen in subjects without cirrhosis. No subjects treated with ZEPATIER or placebo had serious adverse reactions. The proportion of subjects treated with ZEPATIER or placebo who permanently discontinued treatment due to adverse reactions was 1% in each group.</p>
                              <table width="65%" id="t3">
                                 <caption>Table 3: Adverse Reactions (All Intensity) Reported in ≥5% of Treatment-Naïve Subjects with HCV Treated with ZEPATIER for 12 Weeks in C-EDGE TN</caption>
                                 <colgroup><col width="32%" align="left" valign="top">
                                 <col width="34%" align="center" valign="top">
                                 <col width="34%" align="center" valign="top">
                                 </colgroup><thead>
                                    <tr stylecode="Botrule">
                                       <th stylecode="Lrule Rrule"></th>
                                       <th stylecode="Rrule" colspan="2">C-EDGE TN</th>
                                    </tr>
                                    <tr>
                                       <th stylecode="Lrule Rrule"></th>
                                       <th stylecode="Rrule">ZEPATIER<br>N=316<br>%<br>12 weeks</th>
                                       <th stylecode="Rrule">Placebo<br>N=105<br>%<br>12 weeks</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Fatigue</td>
                                       <td stylecode="Rrule">11%</td>
                                       <td stylecode="Rrule">10%</td>
                                    </tr>
                                    <tr>
                                       <td stylecode="Lrule Rrule">Headache</td>
                                       <td stylecode="Rrule">10%</td>
                                       <td stylecode="Rrule">9%</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <p>C-EDGE COINFECTION was a Phase 3 open-label trial in 218 treatment-naïve HCV/HIV co-infected subjects who received ZEPATIER one tablet once daily for 12 weeks. Adverse reactions (all intensity) reported in C-EDGE COINFECTION in at least 5% of subjects treated with ZEPATIER for 12 weeks were fatigue (7%), headache (7%), nausea (5%), insomnia (5%), and diarrhea (5%). No subjects reported serious adverse reactions or discontinued treatment due to adverse reactions. No subjects switched their antiretroviral therapy regimen due to loss of plasma HIV-1 RNA suppression. Median increase in CD4+ T-cell counts of 31 cells per mm<sup>3</sup> was observed at the end of 12 weeks of treatment. </p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Adverse Reactions with ZEPATIER with or without Ribavirin in Treatment-Experienced Subjects </content>
                              </p>
                              <p>C-EDGE TE was a Phase 3 randomized, open-label trial in treatment-experienced (TE) subjects. Adverse reactions of moderate or severe intensity reported in C-EDGE TE in at least 2% of subjects treated with ZEPATIER one tablet once daily for 12 weeks or ZEPATIER one tablet once daily with ribavirin for 16 weeks are presented in <a href="#t4">Table 4</a>. No subjects treated with ZEPATIER without ribavirin for 12 weeks reported serious adverse reactions or discontinued treatment due to adverse reactions. The proportion of subjects treated with ZEPATIER with ribavirin for 16 weeks with serious adverse reactions was 1%. The proportion of subjects treated with ZEPATIER with ribavirin for 16 weeks who permanently discontinued treatment due to adverse reactions was 3%. The type and severity of adverse reactions in subjects with cirrhosis were comparable to those seen in subjects without cirrhosis. </p>
                              <table width="65%" id="t4">
                                 <caption>Table 4: Adverse Reactions (Moderate or Severe Intensity) Reported in ≥2% of PegIFN/RBV-Experienced Subjects with HCV Treated with ZEPATIER for 12 Weeks or ZEPATIER + Ribavirin for 16 Weeks in C-EDGE TE</caption>
                                 <colgroup><col width="30%" align="left" valign="top">
                                 <col width="30%" align="center" valign="top">
                                 <col width="40%" align="center" valign="top">
                                 </colgroup><thead>
                                    <tr stylecode="Botrule">
                                       <th stylecode="Lrule Rrule"></th>
                                       <th stylecode="Rrule" colspan="2">C-EDGE TE</th>
                                    </tr>
                                    <tr>
                                       <th stylecode="Lrule Rrule"></th>
                                       <th stylecode="Rrule">ZEPATIER<br>N=105<br>%<br>12 weeks</th>
                                       <th stylecode="Rrule">ZEPATIER + Ribavirin<br>N=106<br>%<br>16 weeks</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Anemia</td>
                                       <td stylecode="Rrule">0%</td>
                                       <td stylecode="Rrule">8%</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Headache</td>
                                       <td stylecode="Rrule">0%</td>
                                       <td stylecode="Rrule">6%</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Fatigue</td>
                                       <td stylecode="Rrule">5%</td>
                                       <td stylecode="Rrule">4%</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Dyspnea</td>
                                       <td stylecode="Rrule">0%</td>
                                       <td stylecode="Rrule">4%</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Rash or Pruritus</td>
                                       <td stylecode="Rrule">0%</td>
                                       <td stylecode="Rrule">4%</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Irritability </td>
                                       <td stylecode="Rrule">1%</td>
                                       <td stylecode="Rrule">3%</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Abdominal pain</td>
                                       <td stylecode="Rrule">2%</td>
                                       <td stylecode="Rrule">2%</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Depression</td>
                                       <td stylecode="Rrule">1%</td>
                                       <td stylecode="Rrule">2%</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Arthralgia</td>
                                       <td stylecode="Rrule">0%</td>
                                       <td stylecode="Rrule">2%</td>
                                    </tr>
                                    <tr>
                                       <td stylecode="Lrule Rrule">Diarrhea</td>
                                       <td stylecode="Rrule">2%</td>
                                       <td stylecode="Rrule">0%</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <p>The type and severity of adverse reactions with ZEPATIER with or without ribavirin in 10 treatment-experienced subjects with HCV/HIV co-infection were comparable to those reported in subjects without HIV co-infection. Median increase in CD4+ T-cell counts of 32 cells/mm<sup>3</sup> was observed at the end of 12 weeks of treatment with ZEPATIER alone. In subjects treated with ZEPATIER with ribavirin for 16 weeks, CD4+ T-cell counts decreased a median of 135 cells per mm<sup>3</sup> at the end of treatment. No subjects switched their antiretroviral therapy regimen due to loss of plasma HIV-1 RNA suppression. No subject experienced an AIDS-related opportunistic infection.</p>
                              <p>C-SALVAGE was a Phase 2 open-label trial in 79 PegIFN/RBV/PI-experienced subjects. Adverse reactions of moderate or severe intensity reported in C-SALVAGE in at least 2% of subjects treated with ZEPATIER once daily with ribavirin for 12 weeks were fatigue (3%) and insomnia (3%). No subjects reported serious adverse reactions or discontinued treatment due to adverse reactions.</p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Adverse Reactions with ZEPATIER in Subjects with Severe Renal Impairment including Subjects on Hemodialysis</content>
                              </p>
                              <p>The safety of elbasvir and grazoprevir in comparison to placebo in subjects with severe renal impairment (Stage 4 or Stage 5 chronic kidney disease, including subjects on hemodialysis) and chronic hepatitis C virus infection with compensated liver disease (with or without cirrhosis) was assessed in 235 subjects (C-SURFER) <content stylecode="italics">[see <a href="#S14.4">Clinical Studies (14.4)</a>]</content>. The adverse reactions (all intensity) occurring in at least 5% of subjects treated with ZEPATIER for 12 weeks are presented in <a href="#t5">Table 5</a>. In subjects treated with ZEPATIER who reported an adverse reaction, 76% had adverse reactions of mild severity. The proportion of subjects treated with ZEPATIER or placebo with serious adverse reactions was less than 1% in each treatment arm, and less than 1% and 3% of subjects, respectively, permanently discontinued treatment due to adverse reactions in each treatment arm. </p>
                              <table width="65%" id="t5">
                                 <caption>Table 5: Adverse Reactions (All Intensity) Reported in ≥5% of Treatment-Naïve or PegIFN/RBV-Experienced Subjects with Stage 4 or 5 Chronic Kidney Disease and HCV Treated with ZEPATIER for 12 Weeks in C-SURFER</caption>
                                 <colgroup><col width="32%" align="left" valign="top">
                                 <col width="34%" align="center" valign="top">
                                 <col width="34%" align="center" valign="top">
                                 </colgroup><thead>
                                    <tr>
                                       <th stylecode="Lrule Rrule"></th>
                                       <th stylecode="Rrule">ZEPATIER<br>N=122<br>%<br>12 weeks</th>
                                       <th stylecode="Rrule">Placebo<br>N=113<br>%<br>12 weeks</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Nausea</td>
                                       <td stylecode="Rrule">11%</td>
                                       <td stylecode="Rrule">8%</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Headache</td>
                                       <td stylecode="Rrule">11%</td>
                                       <td stylecode="Rrule">5%</td>
                                    </tr>
                                    <tr>
                                       <td stylecode="Lrule Rrule">Fatigue</td>
                                       <td stylecode="Rrule">5%</td>
                                       <td stylecode="Rrule">8%</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Laboratory Abnormalities in Subjects Receiving ZEPATIER with or without Ribavirin</content>
                              </p>
                           </text></div>
</div>
</div>
<div class="section riskhide">
<div id="nonCollapsableElement_34073-7">
<div class="drugSubheadings">
<span id="ZEPATIER_34073-7" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>7 DRUG INTERACTIONS</div>
<div id="ZEPATIER_previewText_34073-7" class="previewText">
                        
                           Co-administration of ZEPATI<span>...</span>
</div>
</div>
<div id="ZEPATIER_collapsableElement_34073-7" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText"><text>
                        <ul ultype="unordered">
                           <li>Co-administration of ZEPATIER with moderate CYP3A inducers is not recommended as they may decrease the plasma concentration of ZEPATIER. (<a href="#S7">7</a>)</li>
                           <li>Co-administration of ZEPATIER with certain strong CYP3A inhibitors is not recommended as they may increase the plasma concentration of ZEPATIER. (<a href="#S7">7</a>)</li>
                           <li>Consult the full prescribing information prior to and during treatment for potential drug interactions. (<a href="#S4">4</a>, <a href="#S5.3">5.3</a>, <a href="#S7">7</a>, <a href="#S12.3">12.3</a>)</li>
                        </ul>
                     </text></div>
<span id="ZEPATIER_collapsableElement_7_1" class="safetySubheading">7.1	Potential for Drug Interactions</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>Grazoprevir is a substrate of OATP1B1/3 transporters. Co-administration of ZEPATIER with drugs that inhibit OATP1B1/3 transporters may result in a significant increase in the plasma concentrations of grazoprevir. As such, co-administration of ZEPATIER with OATP1B1/3 inhibitors is contraindicated <content stylecode="italics">[see <a href="#S4">Contraindications (4)</a>, <a href="#S12.3">Clinical Pharmacology (12.3)</a>], and <a href="#t2">Table 2</a>
                           </content>.</p>
                        <p>Elbasvir and grazoprevir are substrates of CYP3A and P-gp, but the role of intestinal P-gp in the absorption of elbasvir and grazoprevir appears to be minimal. Co-administration of moderate or strong inducers of CYP3A with ZEPATIER may decrease elbasvir and grazoprevir plasma concentrations, leading to reduced therapeutic effect of ZEPATIER. Co-administration of ZEPATIER with strong CYP3A inducers or efavirenz is contraindicated <content stylecode="italics">[see <a href="#S4">Contraindications (4)</a>, <a href="#S12.3">Clinical Pharmacology (12.3)</a>], and <a href="#t2">Table 2</a>.</content> Co-administration of ZEPATIER with moderate CYP3A inducers is not recommended <content stylecode="italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>, <a href="#S12.3">Clinical Pharmacology (12.3)</a>], and <a href="#t6">Table 6</a>.</content> Co-administration of ZEPATIER with strong CYP3A inhibitors may increase elbasvir and grazoprevir concentrations. Co-administration of ZEPATIER with certain strong CYP3A inhibitors is not recommended <content stylecode="italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>, <a href="#S12.3">Clinical Pharmacology (12.3)</a>], and <a href="#t6">Table 6</a>
                           </content>. </p>
                     </text></div>
<span id="ZEPATIER_collapsableElement_7_2" class="safetySubheading">7.2	Established and other Potentially Significant Drug Interactions</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>If dose adjustments of concomitant medications are made due to treatment with ZEPATIER, doses should be readjusted after administration of ZEPATIER is completed. </p>
                        <p>
                           <a href="#t6">Table 6</a> provides a uling of established or potentially clinically significant drug interactions. The drug interactions described are based on studies conducted with either ZEPATIER, the components of ZEPATIER (elbasvir [EBR] and grazoprevir [GZR]) as individual agents, or are predicted drug interactions that may occur with ZEPATIER <content stylecode="italics">[see <a href="#S4">Contraindications (4)</a>, <a href="#S5.3">Warnings and Precautions (5.3)</a>, and <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</content>.</p>
                        <table width="90%" id="t6">
                           <caption>Table 6: Potentially Significant Drug Interactions: Alteration in Dose May Be Recommended Based on Results from Drug Interaction Studies or Predicted Interactions<footnote id="t6f1">This table is not all inclusive.</footnote>
                           </caption>
                           <colgroup><col width="25%" align="left" valign="top">
                           <col width="20%" align="left" valign="top">
                           <col width="55%" align="left" valign="top">
                           </colgroup><thead>
                              <tr>
                                 <th stylecode="Lrule Rrule" align="center">Concomitant Drug Class: Drug Name</th>
                                 <th stylecode="Rrule" align="center">Effect on Concentration<footnote id="t6f2">↓ = decrease, ↑ = increase</footnote>
                                 </th>
                                 <th stylecode="Rrule" align="center">Clinical Comment</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">
                                    <content stylecode="bold">Antibiotics</content>:<br>nafcillin</td>
                                 <td stylecode="Rrule">↓ EBR <br>↓ GZR</td>
                                 <td stylecode="Rrule">Co-administration of ZEPATIER with nafcillin, a moderate CYP3A inducer, may decrease EBR and GZR concentrations, leading to reduced therapeutic effect of ZEPATIER. Co-administration is not recommended.</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">
                                    <content stylecode="bold">Antifungals:</content>
                                    <br>ketoconazole<footnote id="t6f3">These interactions have been studied in healthy adults.</footnote>
                                 </td>
                                 <td stylecode="Rrule">↑ EBR<br>↑ GZR</td>
                                 <td stylecode="Rrule">Concomitant use of systemic ketoconazole and ZEPATIER increases grazoprevir exposure and may increase the overall risk of hepatotoxicity; co-administration of ketoconazole is not recommended.</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">
                                    <content stylecode="bold">Endothelin Antagonists:</content>
                                    <br>bosentan</td>
                                 <td stylecode="Rrule">↓ EBR <br>↓ GZR</td>
                                 <td stylecode="Rrule">Co-administration of ZEPATIER with bosentan, a moderate CYP3A inducer, may decrease EBR and GZR concentrations, leading to reduced therapeutic effect of ZEPATIER. Co-administration is not recommended.</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">
                                    <content stylecode="bold">Immunosuppressants:</content>
                                    <br>tacrolimus<footnoteref idref="t6f3"></footnoteref>
                                 </td>
                                 <td stylecode="Rrule">↑ tacrolimus</td>
                                 <td stylecode="Rrule">Co-administration of ZEPATIER with systemic tacrolimus increases the concentrations of tacrolimus. Frequent monitoring of tacrolimus whole blood concentrations, changes in renal function, and tacrolimus-associated adverse events upon the initiation of co-administration is recommended.</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule" colspan="3">
                                    <content stylecode="bold">HIV Medications:</content>
                                 </td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">etravirine</td>
                                 <td stylecode="Rrule">↓ EBR <br>↓ GZR</td>
                                 <td stylecode="Rrule">Co-administration of ZEPATIER with etravirine, a moderate CYP3A inducer, may decrease EBR and GZR concentrations, leading to reduced therapeutic effect of ZEPATIER. Co-administration is not recommended.</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">elvitegravir/ cobicistat/ emtricitabine/ tenofovir (disoproxil fumarate or alafenamide)</td>
                                 <td stylecode="Rrule">↑ EBR <br>↑ GZR</td>
                                 <td stylecode="Rrule">Co-administration of ZEPATIER with these cobicistat-containing regimens may increase the concentrations of EBR and GZR. Co-administration is not recommended.</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule" colspan="3">
                                    <content stylecode="bold">HMG-CoA Reductase Inhibitors<footnote id="t6f4">
                                          <content stylecode="italics">See <a href="#S7.3">Drug Interactions (7.3)</a>
                                          </content> for a ul of HMG Co-A reductase inhibitors without clinically relevant interactions with ZEPATIER.</footnote>:</content>
                                 </td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">atorvastatin<footnoteref idref="t6f3"></footnoteref>
                                 </td>
                                 <td stylecode="Rrule">↑ atorvastatin</td>
                                 <td stylecode="Rrule">Co-administration of EBR and GZR with atorvastatin increases the concentrations of atorvastatin. The dose of atorvastatin should not exceed a daily dose of 20 mg when co-administered with ZEPATIER.<footnoteref idref="t6f4"></footnoteref>
                                 </td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">rosuvastatin<footnoteref idref="t6f3"></footnoteref>
                                 </td>
                                 <td stylecode="Rrule">↑ rosuvastatin</td>
                                 <td stylecode="Rrule">Co-administration of EBR and GZR with rosuvastatin increases the concentrations of rosuvastatin. The dose of rosuvastatin should not exceed a daily dose of 10 mg when co-administered with ZEPATIER.<footnoteref idref="t6f4"></footnoteref>
                                 </td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">fluvastatin<br>lovastatin<br>simvastatin</td>
                                 <td stylecode="Rrule">↑ fluvastatin<br>↑ lovastatin<br>↑ simvastatin</td>
                                 <td stylecode="Rrule">Co-administration of ZEPATIER with these statins has not been studied but may increase the concentrations of these statins. Statin-associated adverse events such as myopathy should be closely monitored. The lowest necessary dose should be used when co-administered with ZEPATIER.<footnoteref idref="t6f4"></footnoteref>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Lrule Rrule">
                                    <content stylecode="bold">Wakefulness-Promoting Agents:</content>
                                    <br>modafinil</td>
                                 <td stylecode="Rrule">↓ EBR <br>↓ GZR</td>
                                 <td stylecode="Rrule">Co-administration of ZEPATIER with modafinil, a moderate CYP3A inducer, may decrease EBR and GZR concentrations, leading to reduced therapeutic effect of ZEPATIER. Co-administration is not recommended.</td>
                              </tr>
                           </tbody>
                        </table>
                     </text></div>
<span id="ZEPATIER_collapsableElement_7_3" class="safetySubheading">7.3	Drugs without Clinically Significant Interactions with ZEPATIER</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>The interaction between the components of ZEPATIER (elbasvir or grazoprevir) or ZEPATIER and the following drugs were evaluated in clinical studies, and no dose adjustments are needed when ZEPATIER is used with the following drugs individually: acid reducing agents (proton pump inhibitors, H2 blockers, antacids), buprenorphine/naloxone, digoxin, dolutegravir, methadone, mycophenolate mofetil, oral contraceptive pills, phosphate binders, pitavastatin, pravastatin, prednisone, raltegravir, ribavirin, rilpivirine, tenofovir disoproxil fumarate, and sofosbuvir <content stylecode="italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</content>. </p>
                        <p>No clinically relevant drug-drug interaction is expected when ZEPATIER is co-administered with abacavir, emtricitabine, entecavir, and lamivudine.</p>
                     </text></div>
</div>
</div>
<div class="section">
<div id="nonCollapsableElement_43684-0">
<div class="drugSubheadings">
<span id="ZEPATIER_43684-0" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>8 USE IN SPECIFIC POPULATIONS</div>
<div id="ZEPATIER_previewText_43684-0" class="previewText"><span>...</span></div>
</div>
<div id="ZEPATIER_collapsableElement_43684-0" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText"></div>
<span id="ZEPATIER_collapsableElement_8_1" class="safetySubheading">8.1 Pregnancy</span><div id="42228-7" class="safetySubdescription"></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="italics underline">Risk Summary </content>
                              </p>
                              <p>No adequate human data are available to establish whether or not ZEPATIER poses a risk to pregnancy outcomes. In animal reproduction studies, no evidence of adverse developmental outcomes was observed with the components of ZEPATIER (elbasvir or grazoprevir) at exposures greater than those in humans at the recommended human dose (RHD) <content stylecode="italics">[see <a href="#Data">Data</a> in (8.1)]</content>. During organogenesis in the rat and rabbit, systemic exposures (AUC) were approximately 10 and 18 times (for elbasvir) and 117 and 41 times (for grazoprevir), respectively, the exposure in humans at the RHD. In rat pre/postnatal developmental studies, maternal systemic exposures (AUC) to elbasvir and grazoprevir were approximately 10 and 78 times, respectively, the exposure in humans at the RHD.</p>
                              <p>The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.</p>
                              <p>If ZEPATIER is administered with ribavirin, the combination regimen is contraindicated in pregnant women and in men whose female partners are pregnant. Refer to the ribavirin prescribing information for more information on use in pregnancy.</p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="italics underline">Data</content>
                              </p>
                           </text></div>
<span id="ZEPATIER_collapsableElement_8_2" class="safetySubheading">8.2	Lactation</span><div id="77290-5" class="safetySubdescription"></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="italics underline">Risk Summary </content>
                              </p>
                              <p>It is not known whether ZEPATIER is present in human breast milk, affects human milk production, or has effects on the breastfed infant. When administered to lactating rats, the components of ZEPATIER (elbasvir and grazoprevir) were present in milk, without effects on growth and development observed in nursing pups <content stylecode="italics">[see <a href="#Data1">Data</a> in (8.2)]</content>.</p>
                              <p>The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ZEPATIER and any potential adverse effects on the breastfed child from ZEPATIER or from the underlying maternal condition. </p>
                              <p>If ZEPATIER is administered with ribavirin, the information for ribavirin with regard to nursing mothers also applies to this combination regimen. Refer to the ribavirin prescribing information for information on use during lactation.</p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="italics underline">Data</content>
                              </p>
                           </text></div>
<span id="ZEPATIER_collapsableElement_8_3" class="safetySubheading">8.3	Females and Males of Reproductive Potential</span><div id="77291-3" class="safetySubdescription"><text>
                        <p>If ZEPATIER is administered with ribavirin, the information for ribavirin with regard to pregnancy testing, contraception, and infertility also applies to this combination regimen. Refer to ribavirin prescribing information for additional information.</p>
                     </text></div>
<span id="ZEPATIER_collapsableElement_8_4" class="safetySubheading">8.4 Pediatric Use</span><div id="34081-0" class="safetySubdescription"><text>
                        <p>Safety and efficacy in pediatric patients have not been established in pediatric patients less than 18 years of age.</p>
                     </text></div>
<span id="ZEPATIER_collapsableElement_8_5" class="safetySubheading">8.5 Geriatric Use</span><div id="34082-8" class="safetySubdescription"><text>
                        <p>Clinical trials of ZEPATIER with or without ribavirin included 187 subjects aged 65 years and over. Higher elbasvir and grazoprevir plasma concentrations were observed in subjects aged 65 years and over. A higher rate of late ALT elevations was observed in subjects aged 65 years and over in clinical trials <content stylecode="italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</content>. However, no dosage adjustment of ZEPATIER is recommended in geriatric patients <content stylecode="italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</content>.</p>
                     </text></div>
<span id="ZEPATIER_collapsableElement_8_6" class="safetySubheading">8.6	Gender </span><div id="42229-5" class="safetySubdescription"><text>
                        <p>Higher elbasvir and grazoprevir plasma concentrations were observed in females compared to males. Females experienced a higher rate of late ALT elevations in clinical trials <content stylecode="italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</content>. However, no dose adjustment of ZEPATIER is recommended based on gender <content stylecode="italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</content>.</p>
                     </text></div>
<span id="ZEPATIER_collapsableElement_8_7" class="safetySubheading">8.7	Race</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>Higher elbasvir and grazoprevir plasma concentrations were observed in Asians compared to Caucasians. Asians experienced a higher rate of late ALT elevations in clinical trials <content stylecode="italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</content>. However, no dose adjustment of ZEPATIER is recommended based on race/ethnicity <content stylecode="italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</content>.</p>
                     </text></div>
<span id="ZEPATIER_collapsableElement_8_8" class="safetySubheading">8.8	Renal Impairment</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>No dosage adjustment of ZEPATIER is recommended in patients with any degree of renal impairment including patients receiving hemodialysis <content stylecode="italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</content>. Administer ZEPATIER with or without ribavirin according to recommendations in <a href="#t1">Table 1</a>
                           <content stylecode="italics">[see <a href="#S2.2">Dosage and Administration (2.2</a>, <a href="#S2.3">2.3)</a>].</content> Refer to the prescribing information for ribavirin tablets for renal dosage adjustment of ribavirin in patients with CrCl less than or equal to 50 mL per minute. </p>
                     </text></div>
<span id="ZEPATIER_collapsableElement_8_9" class="safetySubheading">8.9	Hepatic Impairment</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>No dosage adjustment of ZEPATIER is recommended in patients with mild hepatic impairment (Child-Pugh A). ZEPATIER is contraindicated in patients with moderate hepatic impairment (Child-Pugh B) due to the lack of clinical safety and efficacy experience in HCV-infected Child-Pugh B patients, and in patients with severe hepatic impairment (Child-Pugh C) due to a 12-fold increase in grazoprevir exposure in non-HCV infected Child-Pugh C subjects <content stylecode="italics">[see <a href="#S2.4">Dosage and Administration (2.4)</a>, <a href="#S4">Contraindications (4)</a>, and <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</content>
                        </p>
                        <p>The safety and efficacy of ZEPATIER have not been established in patients awaiting liver transplant or in liver transplant recipients. </p>
                     </text></div>
</div>
</div>
<div class="section">
<div id="nonCollapsableElement_34088-5">
<div class="drugSubheadings">
<span id="ZEPATIER_34088-5" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>10 OVERDOSAGE</div>
<div id="ZEPATIER_previewText_34088-5" class="previewText">
                  Human experience of overdose with ZEPATIER is limited. No spe<span>...</span>
</div>
</div>
<div id="ZEPATIER_collapsableElement_34088-5" style="margin-left:68px; margin-top: 20px;" class="collapseElement"><div class="descriptionText"><text>
                  <p>Human experience of overdose with ZEPATIER is limited. No specific antidote is available for overdose with ZEPATIER. In case of overdose, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions and appropriate symptomatic treatment instituted. </p>
                  <p>Hemodialysis does not remove elbasvir or grazoprevir since elbasvir and grazoprevir are highly bound to plasma protein <content stylecode="italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</content>. </p>
               </text></div></div>
</div>
<div class="section">
<div id="nonCollapsableElement_34089-3">
<div class="drugSubheadings">
<span id="ZEPATIER_34089-3" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>11 DESCRIPTION</div>
<div id="ZEPATIER_previewText_34089-3" class="previewText">
                  ZEPATIER is a fixed-dose combination tablet containing elbasv<span>...</span>
</div>
</div>
<div id="ZEPATIER_collapsableElement_34089-3" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText"><text>
                  <p>ZEPATIER is a fixed-dose combination tablet containing elbasvir and grazoprevir for oral administration.</p>
                  <p>Elbasvir is an HCV NS5A inhibitor, and grazoprevir is an HCV NS3/4A protease inhibitor.</p>
                  <p>Each tablet contains 50 mg elbasvir and 100 mg grazoprevir. The tablets include the following inactive ingredients: colloidal silicon dioxide, copovidone, croscarmellose sodium, hypromellose, lactose monohydrate, magnesium stearate, mannitol, microcrystalline cellulose, sodium chloride, sodium lauryl sulfate, and vitamin E polyethylene glycol succinate. The tablets are film-coated with a coating material containing the following inactive ingredients: carnauba wax, ferrosoferric oxide, hypromellose, iron oxide red, iron oxide yellow, lactose monohydrate, titanium dioxide, and triacetin.</p>
               </text></div>
<span id="ZEPATIER_collapsableElement_" class="safetySubheading"></span><div id="42229-5" class="safetySubdescription"><text>
                        <p>
                           <content stylecode="underline">Elbasvir: </content>
                        </p>
                        <p>The IUPAC name for elbasvir is Dimethyl <content stylecode="italics">N</content>,<content stylecode="italics">N'</content>-([(6<content stylecode="italics">S</content>)-6-phenylindolo[1,2-<content stylecode="italics">c</content>][1,3]benzoxazine-3,10-diyl]bis{1<content stylecode="italics">H</content>-imidazole-5,2-diyl-(2<content stylecode="italics">S</content>)-pyrrolidine-2,1-diyl[(2<content stylecode="italics">S</content>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate.</p>
                        <p>It has a molecular formula of C<sub>49</sub>H<sub>55</sub>N<sub>9</sub>O<sub>7</sub> and a molecular weight of 882.02. It has the following structural formula:</p>
                        <p>
                           <rendermultimedia referencedobject="MM1"></rendermultimedia>
                        </p>
                        <p>Elbasvir is practically insoluble in water (less than 0.1 mg per mL) and very slightly soluble in ethanol (0.2 mg per mL), but is very soluble in ethyl acetate and acetone.</p>
                     </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div></div>
<span id="ZEPATIER_collapsableElement_" class="safetySubheading"></span><div id="42229-5" class="safetySubdescription"><text>
                        <p>
                           <content stylecode="underline">Grazoprevir: </content>
                        </p>
                        <p>The IUPAC name for grazoprevir is (1a<content stylecode="italics">R</content>,5<content stylecode="italics">S</content>,8<content stylecode="italics">S</content>,10<content stylecode="italics">R</content>,22a<content stylecode="italics">R</content>)-<content stylecode="italics">N</content>-[(1<content stylecode="italics">R</content>,2<content stylecode="italics">S</content>)-1-[(Cyclopropylsulfonamido)carbonyl]-2-ethenylcyclopropyl]-14-methoxy-5-(2-methylpropan-2-yl)-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8<content stylecode="italics">H</content>-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-<content stylecode="italics">b</content>]quinoxaline-8-carboxamide.</p>
                        <p>It has a molecular formula of C<sub>38</sub>H<sub>50</sub>N<sub>6</sub>O<sub>9</sub>S and a molecular weight of 766.90. It has the following structural formula:</p>
                        <p>
                           <rendermultimedia referencedobject="MM2"></rendermultimedia>
                        </p>
                        <p>Grazoprevir is practically insoluble in water (less than 0.1 mg per mL) but is freely soluble in ethanol and some organic solvents (e.g., acetone, tetrahydrofuran and N,N-dimethylformamide).</p>
                     </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div></div>
</div>
</div>
<div class="section">
<div id="nonCollapsableElement_34090-1">
<div class="drugSubheadings">
<span id="ZEPATIER_34090-1" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>12 CLINICAL PHARMACOLOGY</div>
<div id="ZEPATIER_previewText_34090-1" class="previewText"><span>...</span></div>
</div>
<div id="ZEPATIER_collapsableElement_34090-1" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText"></div>
<span id="ZEPATIER_collapsableElement_12_1" class="safetySubheading">12.1	Mechanism of Action</span><div id="43679-0" class="safetySubdescription"><text>
                        <p>ZEPATIER is a fixed-dose combination of elbasvir and grazoprevir which are direct-acting antiviral agents against the hepatitis C virus <content stylecode="italics">[see <a href="#S12.4">Microbiology (12.4)</a>].</content>
                        </p>
                     </text></div>
<span id="ZEPATIER_collapsableElement_12_2" class="safetySubheading">12.2 Pharmacodynamics</span><div id="43681-6" class="safetySubdescription"></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Cardiac Electrophysiology </content>
                              </p>
                              <p>Thorough QT studies have been conducted for elbasvir and grazoprevir. </p>
                              <p>The effect of elbasvir 700 mg on QTc interval was evaluated in a randomized, single-dose, placebo- and active-controlled (moxifloxacin 400 mg) 3-period crossover thorough QT trial in 42 healthy subjects. At a concentration 3 to 4 times the therapeutic concentration, elbasvir does not prolong QTc to any clinically relevant extent.</p>
                              <p>The effect of grazoprevir 1600 mg (16 times the approved dose) on QTc interval was evaluated in a randomized, single-dose, placebo- and active-controlled (moxifloxacin 400 mg) 3-period crossover thorough QT trial in 41 healthy subjects. At a concentration 40 times the therapeutic concentration, grazoprevir does not prolong QTc to any clinically relevant extent.</p>
                           </text></div>
<span id="ZEPATIER_collapsableElement_12_3" class="safetySubheading">12.3 Pharmacokinetics</span><div id="43682-4" class="safetySubdescription"><text>
                        <p>The pharmacokinetic properties of elbasvir and grazoprevir have been evaluated in non-HCV-infected adult subjects and in HCV-infected adult subjects. Elbasvir pharmacokinetics were similar in healthy subjects and HCV-infected subjects and were approximately dose-proportional over the range of 5-100 mg once daily. Grazoprevir oral exposures are approximately 2-fold greater in HCV-infected subjects as compared to healthy subjects. Grazoprevir pharmacokinetics increased in a greater than dose-proportional manner over the range of 10-800 mg once daily in HCV-infected subjects. Ribavirin co-administration with ZEPATIER had no clinically relevant impact on plasma AUC and C<sub>max</sub> of elbasvir and grazoprevir compared to administration of ZEPATIER alone. The geometric mean steady-state pharmacokinetic parameter values for elbasvir and grazoprevir in non-cirrhotic HCV-infected subjects are provided in <a href="#t7">Table 7</a>. Following once daily administration of ZEPATIER to HCV-infected subjects, elbasvir and grazoprevir reached steady state within approximately 6 days.</p>
                        <table width="75%" id="t7">
                           <caption>Table 7: Geometric Mean (90% Confidence Interval) for Elbasvir and Grazoprevir Steady State Pharmacokinetic Parameter Values in Non-Cirrhotic HCV-Infected Subjects Estimated Based on Population Pharmacokinetic Modeling</caption>
                           <colgroup><col width="15%" align="center" valign="bottom">
                           <col width="30%" align="center" valign="bottom">
                           <col width="25%" align="center" valign="bottom">
                           <col width="30%" align="center" valign="bottom">
                           </colgroup><thead>
                              <tr stylecode="Botrule">
                                 <th stylecode="Rrule Lrule" rowspan="2"></th>
                                 <th stylecode="Rrule" colspan="3">Geometric Mean (90% Confidence Interval)</th>
                              </tr>
                              <tr>
                                 <th stylecode="Rrule Lrule">AUC<sub>0-24</sub> (ng•hr/mL)</th>
                                 <th stylecode="Rrule">C<sub>max</sub> (ng/mL)</th>
                                 <th stylecode="Rrule">C<sub>24</sub> (ng/mL)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr stylecode="Botrule">
                                 <td stylecode="Rrule Lrule">Elbasvir</td>
                                 <td stylecode="Rrule">1920 (1880, 1960)</td>
                                 <td stylecode="Rrule">121 (118, 123)</td>
                                 <td stylecode="Rrule">48.4 (47.3, 49.6)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule Lrule">Grazoprevir</td>
                                 <td stylecode="Rrule">1420 (1400, 1530)</td>
                                 <td stylecode="Rrule">165 (161, 176)</td>
                                 <td stylecode="Rrule">18.0 (17.8,19.9)</td>
                              </tr>
                           </tbody>
                        </table>
                     </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Absorption</content>
                              </p>
                              <p>Following administration of ZEPATIER to HCV-infected subjects, elbasvir peak concentrations occur at a median T<sub>max</sub> of 3 hours (range of 3 to 6 hours); grazoprevir peak concentrations occur at a median T<sub>max</sub> of 2 hours (range of 30 minutes to 3 hours). </p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Distribution</content>
                              </p>
                              <p>Elbasvir and grazoprevir are extensively bound (greater than 99.9% and 98.8%, respectively) to human plasma proteins. Both elbasvir and grazoprevir bind to human serum albumin and α1-acid glycoprotein. Estimated apparent volume of distribution values of elbasvir and grazoprevir are approximately 680 L and 1250 L, respectively, based on population pharmacokinetic modeling. </p>
                              <p>In preclinical distribution studies, elbasvir distributes into most tissues including the liver; whereas grazoprevir distributes predominantly to the liver likely facilitated by the active transport through the OATP1B1/3 liver uptake transporter. </p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Elimination</content>
                              </p>
                              <p>The geometric mean apparent terminal half-life for elbasvir (50 mg) and grazoprevir (100 mg) is approximately 24 and 31 hours, respectively, in HCV-infected subjects. </p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Specific Populations</content>
                              </p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Drug Interaction Studies </content>
                              </p>
                              <p>Drug interaction studies were performed in healthy adults with elbasvir, grazoprevir, or co-administered elbasvir and grazoprevir and drugs likely to be co-administered or drugs commonly used as probes for pharmacokinetic interactions. <a href="#t8">Table 8</a> summarizes the effects of co-administered drugs on the exposures of the individual components of ZEPATIER (elbasvir and grazoprevir). <a href="#t9">Table 9</a> summarizes the effects of the individual components of ZEPATIER on the exposures of the co-administered drugs. For information regarding clinical recommendations, <content stylecode="italics">[see <a href="#S4">Contraindications (4)</a>, <a href="#S5.3">Warnings and Precautions (5.3)</a>
                                    <a></a>, and <a href="#S7">Drug Interactions (7)</a>].</content>
                              </p>
                              <p>Elbasvir and grazoprevir are substrates of CYP3A and P-gp, but the role of intestinal P-gp in the absorption of elbasvir and grazoprevir appears to be minimal. Co-administration of moderate and strong CYP3A inducers with ZEPATIER may decrease elbasvir and grazoprevir plasma concentrations, leading to reduced therapeutic effect of ZEPATIER. Co-administration of strong CYP3A4 inhibitors with ZEPATIER may increase elbasvir and grazoprevir plasma concentrations.</p>
                              <p>Grazoprevir is a substrate of OATP1B1/3. Co-administration of ZEPATIER with drugs that inhibit OATP1B1/3 transporters may result in a clinically relevant increase in grazoprevir plasma concentrations. </p>
                              <p>Elbasvir is not a CYP3A inhibitor <content stylecode="italics">in vitro</content> and grazoprevir is a weak CYP3A inhibitor in humans. Co-administration with grazoprevir resulted in a 34% increase in plasma exposure of midazolam and a 43% increase in plasma exposure of tacrolimus (see <a href="#t6">Tables 6</a> and <a href="#t9">9</a>). Elbasvir inhibited P-gp <content stylecode="italics">in vitro</content>, but no clinically relevant increases in concentrations of digoxin (a P-gp substrate; see <a href="#t9">Table 9</a>) were observed by co-administration of elbasvir. Grazoprevir is not a P-gp inhibitor <content stylecode="italics">in vitro</content>. Elbasvir and grazoprevir are inhibitors of the drug transporter breast cancer resistance protein (BCRP) at the intestinal level in humans and may increase plasma concentrations of co-administered BCRP substrates. </p>
                              <p>Clinically significant drug interactions with ZEPATIER as an inhibitor of other CYP enzymes (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6), UGT1A1, and esterases (CES1, CES2, and CatA), are not expected, and multiple-dose administration of elbasvir or grazoprevir is unlikely to induce the metabolism of drugs metabolized by CYP1A2, CYP2B6, or CYP3A based on <content stylecode="italics">in vitro</content> data. </p>
                              <table width="100%" id="t8">
                                 <caption>Table 8: Drug Interactions: Changes in Pharmacokinetics of Elbasvir or Grazoprevir in the Presence of Co-Administered Drug</caption>
                                 <colgroup><col width="11%" align="center" valign="middle">
                                 <col width="12%" align="center" valign="middle">
                                 <col width="13%" align="center" valign="middle">
                                 <col width="7%" align="center" valign="middle">
                                 <col width="12%" align="center" valign="middle">
                                 <col width="15%" align="center" valign="middle">
                                 <col width="15%" align="center" valign="middle">
                                 <col width="15%" align="center" valign="middle">
                                 </colgroup><thead>
                                    <tr stylecode="Botrule">
                                       <th stylecode="Lrule Rrule" rowspan="2">Co-Administered Drug</th>
                                       <th stylecode="Rrule" rowspan="2">Regimen of Co-Administered Drug</th>
                                       <th stylecode="Rrule" rowspan="2">Regimen of EBR or/and GZR</th>
                                       <th stylecode="Rrule" rowspan="2">N</th>
                                       <th stylecode="Rrule" colspan="4">Geometric Mean Ratio [90% CI] of EBR and GZR PK with/without Co-Administered Drug (No Effect=1.00)</th>
                                    </tr>
                                    <tr>
                                       <th stylecode="Rrule"></th>
                                       <th stylecode="Rrule">AUC<footnote id="t8f1">AUC<sub>0-inf</sub> for single-dose, AUC<sub>0-24</sub> for once daily.</footnote>
                                       </th>
                                       <th stylecode="Rrule">C<sub>max</sub>
                                       </th>
                                       <th stylecode="Rrule">C24</th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td align="left" valign="top" colspan="8">Abbreviations: EBR, elbasvir; GZR, grazoprevir; IV, intravenous; PO, oral; EBR + GZR, administration of EBR and GZR as separate pills; EBR/GZR, administration of EBR and GZR as a single fixed-dose combination tablet.</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" colspan="8">Antifungal</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" rowspan="2">Ketoconazole</td>
                                       <td stylecode="Rrule">400 mg once daily</td>
                                       <td stylecode="Rrule">EBR 50 mg single-dose</td>
                                       <td stylecode="Rrule">7</td>
                                       <td stylecode="Rrule">EBR</td>
                                       <td stylecode="Rrule">1.80 (1.41, 2.29)</td>
                                       <td stylecode="Rrule">1.29 (1.00, 1.66)</td>
                                       <td stylecode="Rrule">1.89 (1.37, 2.60)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">400 mg once daily</td>
                                       <td stylecode="Rrule">GZR 100 mg single-dose</td>
                                       <td stylecode="Rrule">8</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">3.02 (2.42, 3.76)</td>
                                       <td stylecode="Rrule">1.13 (0.77, 1.67)</td>
                                       <td stylecode="Rrule">2.01 (1.49, 2.71)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" colspan="8">Antimycobacterial</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" rowspan="5">Rifampin</td>
                                       <td stylecode="Rrule">600 mg single-dose IV</td>
                                       <td stylecode="Rrule">EBR 50 mg single-dose</td>
                                       <td stylecode="Rrule">14</td>
                                       <td stylecode="Rrule">EBR</td>
                                       <td stylecode="Rrule">1.22 (1.06, 1.40)</td>
                                       <td stylecode="Rrule">1.41 (1.18, 1.68)</td>
                                       <td stylecode="Rrule">1.31 (1.12, 1.53)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">600 mg single-dose PO</td>
                                       <td stylecode="Rrule">EBR 50 mg single-dose</td>
                                       <td stylecode="Rrule">14</td>
                                       <td stylecode="Rrule">EBR</td>
                                       <td stylecode="Rrule">1.17 (0.98, 1.39)</td>
                                       <td stylecode="Rrule">1.29 (1.06, 1.58)</td>
                                       <td stylecode="Rrule">1.21 (1.03, 1.43)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">600 mg PO once daily</td>
                                       <td stylecode="Rrule">GZR 200 mg once daily</td>
                                       <td stylecode="Rrule">12</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">0.93 (0.75, 1.17)</td>
                                       <td stylecode="Rrule">1.16 (0.82, 1.65)</td>
                                       <td stylecode="Rrule">0.10 (0.07, 0.13)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">600 mg IV single-dose</td>
                                       <td stylecode="Rrule">GZR 200 mg single-dose</td>
                                       <td stylecode="Rrule">12</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">10.21 (8.68, 12.00)</td>
                                       <td stylecode="Rrule">10.94 (8.92, 13.43)</td>
                                       <td stylecode="Rrule">1.77 (1.40, 2.24)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">600 mg PO single-dose</td>
                                       <td stylecode="Rrule">GZR 200 mg once daily</td>
                                       <td stylecode="Rrule">12</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">8.35 (7.38, 9.45)<footnote id="t8f2">AUC<sub>0-24</sub>
                                          </footnote>
                                       </td>
                                       <td stylecode="Rrule">6.52 (5.16, 8.24)</td>
                                       <td stylecode="Rrule">1.62 (1.32, 1.98)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" colspan="8">HCV Antiviral</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">EBR</td>
                                       <td stylecode="Rrule">20 mg once daily</td>
                                       <td stylecode="Rrule">GZR 200 mg once daily</td>
                                       <td stylecode="Rrule">10</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">0.90 (0.63, 1.28)</td>
                                       <td stylecode="Rrule">0.87 (0.50, 1.52)</td>
                                       <td stylecode="Rrule">0.94 (0.77, 1.15)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">GZR</td>
                                       <td stylecode="Rrule">200 mg once daily</td>
                                       <td stylecode="Rrule">EBR 20 mg once daily</td>
                                       <td stylecode="Rrule">10</td>
                                       <td stylecode="Rrule">EBR</td>
                                       <td stylecode="Rrule">1.01 (0.83, 1.24)</td>
                                       <td stylecode="Rrule">0.93 (0.76, 1.13)</td>
                                       <td stylecode="Rrule">1.02 (0.83, 1.24)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" colspan="8">HIV Protease Inhibitor</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" rowspan="2">Atazanavir/ ritonavir</td>
                                       <td stylecode="Rrule">300 mg/100 mg once daily</td>
                                       <td stylecode="Rrule">EBR 50 mg once daily</td>
                                       <td stylecode="Rrule">10</td>
                                       <td stylecode="Rrule">EBR</td>
                                       <td stylecode="Rrule">4.76 (4.07, 5.56)</td>
                                       <td stylecode="Rrule">4.15 (3.46, 4.97)</td>
                                       <td stylecode="Rrule">6.45 (5.51, 7.54)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">300 mg/100 mg once daily</td>
                                       <td stylecode="Rrule">GZR 200 mg once daily</td>
                                       <td stylecode="Rrule">12</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">10.58 (7.78, 14.39)</td>
                                       <td stylecode="Rrule">6.24 (4.42, 8.81)</td>
                                       <td stylecode="Rrule">11.64 (7.96, 17.02)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" rowspan="2">Darunavir/ ritonavir</td>
                                       <td stylecode="Rrule">600 mg/100 mg twice daily</td>
                                       <td stylecode="Rrule">EBR 50 mg once daily</td>
                                       <td stylecode="Rrule">10</td>
                                       <td stylecode="Rrule">EBR</td>
                                       <td stylecode="Rrule">1.66 (1.35, 2.05)</td>
                                       <td stylecode="Rrule">1.67 (1.36, 2.05)</td>
                                       <td stylecode="Rrule">1.82 (1.39, 2.39)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">600 mg/100 mg twice daily</td>
                                       <td stylecode="Rrule">GZR 200 mg once daily</td>
                                       <td stylecode="Rrule">13</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">7.50 (5.92, 9.51)</td>
                                       <td stylecode="Rrule">5.27 (4.04, 6.86)</td>
                                       <td stylecode="Rrule">8.05 (6.33, 10.24)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" rowspan="2">Lopinavir/ ritonavir</td>
                                       <td stylecode="Rrule">400 mg/100 mg twice daily</td>
                                       <td stylecode="Rrule">EBR 50 mg once daily</td>
                                       <td stylecode="Rrule">10</td>
                                       <td stylecode="Rrule">EBR</td>
                                       <td stylecode="Rrule">3.71 (3.05, 4.53)</td>
                                       <td stylecode="Rrule">2.87 (2.29, 3.58)</td>
                                       <td stylecode="Rrule">4.58 (3.72, 5.64)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">400 mg/100 mg twice daily</td>
                                       <td stylecode="Rrule">GZR 200 mg once daily</td>
                                       <td stylecode="Rrule">13</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">12.86 (10.25, 16.13)</td>
                                       <td stylecode="Rrule">7.31 (5.65, 9.45)</td>
                                       <td stylecode="Rrule">21.70 (12.99, 36.25)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Ritonavir<footnote id="t83">Higher doses of ritonavir have not been tested in a drug interaction study with GZR.</footnote>
                                       </td>
                                       <td stylecode="Rrule">100 mg twice daily</td>
                                       <td stylecode="Rrule">GZR 200 mg single-dose</td>
                                       <td stylecode="Rrule">10</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">2.03 (1.60, 2.56)</td>
                                       <td stylecode="Rrule">1.15 (0.60, 2.18)</td>
                                       <td stylecode="Rrule">1.88 (1.65, 2.14)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" colspan="8">HIV Integrase Strand Transfer Inhibitor</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" rowspan="2">Dolutegravir</td>
                                       <td stylecode="Rrule">50 mg single-dose</td>
                                       <td stylecode="Rrule">EBR 50 mg + GZR 200 mg once daily</td>
                                       <td stylecode="Rrule">12</td>
                                       <td stylecode="Rrule">EBR</td>
                                       <td stylecode="Rrule">0.98 (0.93, 1.04)</td>
                                       <td stylecode="Rrule">0.97 (0.89, 1.05)</td>
                                       <td stylecode="Rrule">0.98 (0.93, 1.03)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">50 mg single-dose</td>
                                       <td stylecode="Rrule">EBR 50 mg + GZR 200 mg once daily</td>
                                       <td stylecode="Rrule">12</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">0.81 (0.67, 0.97)</td>
                                       <td stylecode="Rrule">0.64 (0.44, 0.93)</td>
                                       <td stylecode="Rrule">0.86 (0.79, 0.93)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" rowspan="2">Raltegravir</td>
                                       <td stylecode="Rrule">400 mg single-dose</td>
                                       <td stylecode="Rrule">EBR 50 mg single-dose</td>
                                       <td stylecode="Rrule">10</td>
                                       <td stylecode="Rrule">EBR</td>
                                       <td stylecode="Rrule">0.81 (0.57, 1.17)</td>
                                       <td stylecode="Rrule">0.89 (0.61, 1.29)</td>
                                       <td stylecode="Rrule">0.80 (0.55, 1.16)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">400 mg twice daily</td>
                                       <td stylecode="Rrule">GZR 200 mg once daily</td>
                                       <td stylecode="Rrule">11</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">0.89 (0.72, 1.09)</td>
                                       <td stylecode="Rrule">0.85 (0.62, 1.16)</td>
                                       <td stylecode="Rrule">0.90 (0.82, 0.99)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" colspan="8">HIV Non-Nucleoside Reverse Transcriptase Inhibitor</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" rowspan="2">Efavirenz</td>
                                       <td stylecode="Rrule">600 mg once daily</td>
                                       <td stylecode="Rrule">EBR 50 mg once daily</td>
                                       <td stylecode="Rrule">10</td>
                                       <td stylecode="Rrule">EBR</td>
                                       <td stylecode="Rrule">0.46 (0.36, 0.59)</td>
                                       <td stylecode="Rrule">0.55 (0.41, 0.73)</td>
                                       <td stylecode="Rrule">0.41 (0.28, 0.59)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">600 mg once daily</td>
                                       <td stylecode="Rrule">GZR 200 mg once daily</td>
                                       <td stylecode="Rrule">12</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">0.17 (0.13, 0.24)</td>
                                       <td stylecode="Rrule">0.13 (0.09, 0.19)</td>
                                       <td stylecode="Rrule">0.31 (0.25, 0.38)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" rowspan="2">Rilpivirine</td>
                                       <td stylecode="Rrule">25 mg once daily</td>
                                       <td stylecode="Rrule">EBR 50 mg + GZR 200 mg once daily</td>
                                       <td stylecode="Rrule">19</td>
                                       <td stylecode="Rrule">EBR</td>
                                       <td stylecode="Rrule">1.07 (1.00, 1.15)</td>
                                       <td stylecode="Rrule">1.07 (0.99, 1.16)</td>
                                       <td stylecode="Rrule">1.04 (0.98, 1.11)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">25 mg once daily</td>
                                       <td stylecode="Rrule">EBR 50 mg + GZR 200 mg once daily</td>
                                       <td stylecode="Rrule">19</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">0.98 (0.89, 1.07)</td>
                                       <td stylecode="Rrule">0.97 (0.83, 1.14)</td>
                                       <td stylecode="Rrule">1.00 (0.93, 1.07)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" colspan="8">HIV Nucleotide Reverse Transcriptase Inhibitor</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" rowspan="2">Tenofovir disoproxil fumarate</td>
                                       <td stylecode="Rrule">300 mg once daily</td>
                                       <td stylecode="Rrule">EBR 50 mg once daily</td>
                                       <td stylecode="Rrule">10</td>
                                       <td stylecode="Rrule">EBR</td>
                                       <td stylecode="Rrule">0.93 (0.82, 1.05)</td>
                                       <td stylecode="Rrule">0.88 (0.77, 1.00)</td>
                                       <td stylecode="Rrule">0.92 (0.81, 1.05)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">300 mg once daily</td>
                                       <td stylecode="Rrule">GZR 200 mg once daily</td>
                                       <td stylecode="Rrule">12</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">0.86 (0.65, 1.12)</td>
                                       <td stylecode="Rrule">0.78 (0.51, 1.18)</td>
                                       <td stylecode="Rrule">0.89 (0.78, 1.01)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" colspan="8">Immunosuppressant</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" rowspan="2">Cyclosporine</td>
                                       <td stylecode="Rrule">400 mg single-dose</td>
                                       <td stylecode="Rrule">EBR 50 mg + GZR 200 mg once daily</td>
                                       <td stylecode="Rrule">14</td>
                                       <td stylecode="Rrule">EBR</td>
                                       <td stylecode="Rrule">1.98 (1.84, 2.13)</td>
                                       <td stylecode="Rrule">1.95 (1.84, 2.07)</td>
                                       <td stylecode="Rrule">2.21 (1.98, 2.47)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">400 mg single-dose</td>
                                       <td stylecode="Rrule">EBR 50 mg + GZR 200 mg once daily</td>
                                       <td stylecode="Rrule">14</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">15.21 (12.83, 18.04)</td>
                                       <td stylecode="Rrule">17.00 (12.94, 22.34)</td>
                                       <td stylecode="Rrule">3.39 (2.82, 4.09)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" rowspan="2">Mycophenolate mofetil</td>
                                       <td stylecode="Rrule">1000 mg single-dose</td>
                                       <td stylecode="Rrule">EBR 50 mg + GZR 200 mg once daily</td>
                                       <td stylecode="Rrule">14</td>
                                       <td stylecode="Rrule">EBR</td>
                                       <td stylecode="Rrule">1.07 (1.00, 1.14)</td>
                                       <td stylecode="Rrule">1.07 (0.98, 1.16)</td>
                                       <td stylecode="Rrule">1.05 (0.97, 1.14)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">1000 mg single-dose</td>
                                       <td stylecode="Rrule">EBR 50 mg + GZR 200 mg once daily</td>
                                       <td stylecode="Rrule">14</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">0.74 (0.60, 0.92)</td>
                                       <td stylecode="Rrule">0.58 (0.42, 0.82)</td>
                                       <td stylecode="Rrule">0.97 (0.89, 1.06)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" rowspan="2">Prednisone</td>
                                       <td stylecode="Rrule">40 mg single-dose</td>
                                       <td stylecode="Rrule">EBR 50 mg + GZR 200 mg once daily</td>
                                       <td stylecode="Rrule">14</td>
                                       <td stylecode="Rrule">EBR</td>
                                       <td stylecode="Rrule">1.17 (1.11, 1.24)</td>
                                       <td stylecode="Rrule">1.25 (1.16, 1.35)</td>
                                       <td stylecode="Rrule">1.04 (0.97, 1.12)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">40 mg single-dose</td>
                                       <td stylecode="Rrule">EBR 50 mg + GZR 200 mg once daily</td>
                                       <td stylecode="Rrule">14</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">1.09 (0.95, 1.25)</td>
                                       <td stylecode="Rrule">1.34 (1.10, 1.62)</td>
                                       <td stylecode="Rrule">0.93 (0.87, 1.00)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" rowspan="2">Tacrolimus</td>
                                       <td stylecode="Rrule">2 mg single-dose</td>
                                       <td stylecode="Rrule">EBR 50 mg + GZR 200 mg once daily</td>
                                       <td stylecode="Rrule">16</td>
                                       <td stylecode="Rrule">EBR</td>
                                       <td stylecode="Rrule">0.97 (0.90, 1.06)</td>
                                       <td stylecode="Rrule">0.99 (0.88, 1.10)</td>
                                       <td stylecode="Rrule">0.92 (0.83, 1.02)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">2 mg single-dose</td>
                                       <td stylecode="Rrule">EBR 50 mg + GZR 200 mg once daily</td>
                                       <td stylecode="Rrule">16</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">1.12 (0.97, 1.30)</td>
                                       <td stylecode="Rrule">1.07 (0.83, 1.37)</td>
                                       <td stylecode="Rrule">0.94 (0.87, 1.02)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" colspan="8">Opioid-Substitution Therapy</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Buprenorphine/naloxone</td>
                                       <td stylecode="Rrule">8 mg/2 mg single-dose</td>
                                       <td stylecode="Rrule">EBR 50 mg single-dose</td>
                                       <td stylecode="Rrule">15</td>
                                       <td stylecode="Rrule">EBR</td>
                                       <td stylecode="Rrule">1.22 (0.98, 1.52)</td>
                                       <td stylecode="Rrule">1.13 (0.87, 1.46)</td>
                                       <td stylecode="Rrule">1.22 (0.99, 1.51)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" colspan="8">Acid-Reducing Agent</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" rowspan="2">Famotidine</td>
                                       <td stylecode="Rrule">20 mg single-dose</td>
                                       <td stylecode="Rrule">EBR 50 mg/ GZR 100 mg single-dose</td>
                                       <td stylecode="Rrule">16</td>
                                       <td stylecode="Rrule">EBR</td>
                                       <td stylecode="Rrule">1.05 (0.92, 1.18)</td>
                                       <td stylecode="Rrule">1.11 (0.98, 1.26)</td>
                                       <td stylecode="Rrule">1.03 (0.91, 1.17)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">20 mg single-dose</td>
                                       <td stylecode="Rrule">EBR 50 mg/ GZR 100 mg single-dose</td>
                                       <td stylecode="Rrule">16</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">1.10 (0.95, 1.28)</td>
                                       <td stylecode="Rrule">0.89 (0.71, 1.11)</td>
                                       <td stylecode="Rrule">1.12 (0.97, 1.30)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" rowspan="2">Pantoprazole</td>
                                       <td stylecode="Rrule">40 mg once daily</td>
                                       <td stylecode="Rrule">EBR 50 mg/ GZR 100 mg single-dose</td>
                                       <td stylecode="Rrule">16</td>
                                       <td stylecode="Rrule">EBR</td>
                                       <td stylecode="Rrule">1.05 (0.93, 1.18)</td>
                                       <td stylecode="Rrule">1.02 (0.92, 1.14)</td>
                                       <td stylecode="Rrule">1.03 (0.92, 1.17)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">40 mg once daily</td>
                                       <td stylecode="Rrule">EBR 50 mg/ GZR 100 mg single-dose</td>
                                       <td stylecode="Rrule">16</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">1.12 (0.96, 1.30)</td>
                                       <td stylecode="Rrule">1.10 (0.89, 1.37)</td>
                                       <td stylecode="Rrule">1.17 (1.02, 1.34)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" colspan="8">Phosphate Binder</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" rowspan="2">Calcium acetate</td>
                                       <td stylecode="Rrule">2668 mg single-dose</td>
                                       <td stylecode="Rrule">EBR 50 mg + GZR 100 mg single-dose</td>
                                       <td stylecode="Rrule">12</td>
                                       <td stylecode="Rrule">EBR</td>
                                       <td stylecode="Rrule">0.92 (0.75, 1.14)</td>
                                       <td stylecode="Rrule">0.86 (0.71, 1.04)</td>
                                       <td stylecode="Rrule">0.87 (0.70, 1.09)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">2668 mg single-dose</td>
                                       <td stylecode="Rrule">EBR 50 mg + GZR 100 mg single-dose</td>
                                       <td stylecode="Rrule">12</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">0.79 (0.68, 0.91)</td>
                                       <td stylecode="Rrule">0.57 (0.40, 0.83)</td>
                                       <td stylecode="Rrule">0.77 (0.61, 0.99)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" rowspan="2">Sevelamer carbonate</td>
                                       <td stylecode="Rrule">2400 mg single-dose</td>
                                       <td stylecode="Rrule">EBR 50 mg + GZR 100 mg single-dose</td>
                                       <td stylecode="Rrule">12</td>
                                       <td stylecode="Rrule">EBR</td>
                                       <td stylecode="Rrule">1.13 (0.94, 1.37)</td>
                                       <td stylecode="Rrule">1.07 (0.88, 1.29)</td>
                                       <td stylecode="Rrule">1.22 (1.02, 1.45)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">2400 mg single-dose</td>
                                       <td stylecode="Rrule">EBR 50 mg + GZR 100 mg single-dose</td>
                                       <td stylecode="Rrule">12</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">0.82 (0.68, 0.99)</td>
                                       <td stylecode="Rrule">0.53 (0.37, 0.76)</td>
                                       <td stylecode="Rrule">0.84 (0.71, 0.99)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" colspan="8">Statin</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Atorvastatin</td>
                                       <td stylecode="Rrule">20 mg single-dose</td>
                                       <td stylecode="Rrule">GZR 200 mg once daily</td>
                                       <td stylecode="Rrule">9</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">1.26 (0.97, 1.64)</td>
                                       <td stylecode="Rrule">1.26 (0.83, 1.90)</td>
                                       <td stylecode="Rrule">1.11 (1.00, 1.23)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Pitavastatin</td>
                                       <td stylecode="Rrule">1 mg single-dose</td>
                                       <td stylecode="Rrule">GZR 200 mg once daily</td>
                                       <td stylecode="Rrule">9</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">0.81 (0.70, 0.95)</td>
                                       <td stylecode="Rrule">0.72 (0.57, 0.92)</td>
                                       <td stylecode="Rrule">0.91 (0.82, 1.01)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" rowspan="2">Pravastatin</td>
                                       <td stylecode="Rrule">40 mg single-dose</td>
                                       <td stylecode="Rrule">EBR 50 mg + GZR 200 mg once daily</td>
                                       <td stylecode="Rrule">12</td>
                                       <td stylecode="Rrule">EBR</td>
                                       <td stylecode="Rrule">0.98 (0.93, 1.02)</td>
                                       <td stylecode="Rrule">0.97 (0.89, 1.05)</td>
                                       <td stylecode="Rrule">0.97 (0.92, 1.02)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">40 mg single-dose</td>
                                       <td stylecode="Rrule">EBR 50 mg + GZR 200 mg once daily</td>
                                       <td stylecode="Rrule">12</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">1.24 (1.00, 1.53)</td>
                                       <td stylecode="Rrule">1.42 (1.00, 2.03)</td>
                                       <td stylecode="Rrule">1.07 (0.99, 1.16)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" rowspan="3">Rosuvastatin</td>
                                       <td stylecode="Rrule">10 mg single-dose</td>
                                       <td stylecode="Rrule">EBR 50 mg + GZR 200 mg single-dose</td>
                                       <td stylecode="Rrule">11</td>
                                       <td stylecode="Rrule">EBR</td>
                                       <td stylecode="Rrule">1.09 (0.98, 1.21)</td>
                                       <td stylecode="Rrule">1.11 (0.99, 1.26)</td>
                                       <td stylecode="Rrule">0.96 (0.86, 1.08)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">10 mg single-dose</td>
                                       <td stylecode="Rrule">GZR 200 mg once daily</td>
                                       <td stylecode="Rrule">11</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">1.16 (0.94, 1.44)</td>
                                       <td stylecode="Rrule">1.13 (0.77, 1.65)</td>
                                       <td stylecode="Rrule">0.93 (0.84, 1.03)</td>
                                    </tr>
                                    <tr>
                                       <td stylecode="Rrule">10 mg single-dose</td>
                                       <td stylecode="Rrule">EBR 50 mg + GZR 200 mg once daily</td>
                                       <td stylecode="Rrule">11</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">1.01 (0.79, 1.28)</td>
                                       <td stylecode="Rrule">0.97 (0.63, 1.50)</td>
                                       <td stylecode="Rrule">0.95 (0.87, 1.04)</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <table width="100%" id="t9">
                                 <caption>Table 9: Drug Interactions: Changes in Pharmacokinetics for Co-Administered Drug in the Presence of Elbasvir, Grazoprevir, or Co-Administered Elbasvir and Grazoprevir</caption>
                                 <colgroup><col width="15%" align="center" valign="middle">
                                 <col width="15%" align="center" valign="middle">
                                 <col width="15%" align="center" valign="middle">
                                 <col width="20%" align="center" valign="middle">
                                 <col width="5%" align="center" valign="middle">
                                 <col width="10%" align="center" valign="middle">
                                 <col width="10%" align="center" valign="middle">
                                 <col width="10%" align="center" valign="middle">
                                 </colgroup><thead>
                                    <tr stylecode="Botrule">
                                       <th stylecode="Lrule Rrule" rowspan="2">Co-Administered Drug</th>
                                       <th stylecode="Rrule" rowspan="2">Regimen of Co-Administered Drug</th>
                                       <th stylecode="Rrule" rowspan="2">EBR or/and GZR Administration</th>
                                       <th stylecode="Rrule" rowspan="2">EBR or/and GZR Regimen</th>
                                       <th stylecode="Rrule" rowspan="2">N</th>
                                       <th stylecode="Rrule" colspan="3">Geometric Mean Ratio [90% CI] of Co-Administered Drug PK with/without EBR or/and GZR (No Effect=1.00)</th>
                                    </tr>
                                    <tr>
                                       <th stylecode="Rrule">AUC<footnote id="t9f1">AUC<sub>0-inf</sub> for single-dose administration; AUC<sub>0-24</sub> for once daily administration; AUC<sub>0-12</sub> for twice daily administration</footnote>
                                       </th>
                                       <th stylecode="Rrule">C<sub>max</sub>
                                       </th>
                                       <th stylecode="Rrule">C<sub>trough</sub>
                                          <footnote id="t9f2">C24 for once daily administration; C12 for twice daily administration.</footnote>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td align="left" valign="top" colspan="8">Abbreviations: EBR, elbasvir; GZR, grazoprevir; EBR + GZR, administration of EBR and GZR as separate tablets</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" colspan="8">P-gp Substrate</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Digoxin</td>
                                       <td stylecode="Rrule">Digoxin 0.25 mg single-dose</td>
                                       <td stylecode="Rrule">EBR</td>
                                       <td stylecode="Rrule">50 mg once daily</td>
                                       <td stylecode="Rrule">18</td>
                                       <td stylecode="Rrule">1.11 (1.02, 1.22)</td>
                                       <td stylecode="Rrule">1.47 (1.25, 1.73)</td>
                                       <td stylecode="Rrule">--</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" colspan="8">CYP3A Substrate</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Midazolam</td>
                                       <td stylecode="Rrule">Midazolam 2 mg single-dose</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">200 mg once daily</td>
                                       <td stylecode="Rrule">11</td>
                                       <td stylecode="Rrule">1.34 (1.29, 1.39)</td>
                                       <td stylecode="Rrule">1.15 (1.01, 1.31)</td>
                                       <td stylecode="Rrule">--</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" colspan="8">CYP2C8 Substrate</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Montelukast</td>
                                       <td stylecode="Rrule">Montelukast 10 mg single-dose</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">200 mg once daily</td>
                                       <td stylecode="Rrule">23</td>
                                       <td stylecode="Rrule">1.11 (1.01, 1.20)</td>
                                       <td stylecode="Rrule">0.92 (0.81, 1.06)</td>
                                       <td stylecode="Rrule">1.39 (1.25, 1.56)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" colspan="8">HCV Antiviral</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">GS-331007</td>
                                       <td stylecode="Rrule">Sofosbuvir 400 mg single-dose</td>
                                       <td stylecode="Rrule">EBR + GZR </td>
                                       <td stylecode="Rrule">50 mg + 200 mg once daily</td>
                                       <td stylecode="Rrule">16</td>
                                       <td stylecode="Rrule">1.13 (1.05, 1.21)</td>
                                       <td stylecode="Rrule">0.87 (0.78, 0.96)</td>
                                       <td stylecode="Rrule">1.53 (1.43, 1.63)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Sofosbuvir</td>
                                       <td stylecode="Rrule">Sofosbuvir 400 mg single-dose</td>
                                       <td stylecode="Rrule">EBR + GZR </td>
                                       <td stylecode="Rrule">50 mg + 200 mg once daily</td>
                                       <td stylecode="Rrule">16</td>
                                       <td stylecode="Rrule">2.43 (2.12, 2.79)<footnote id="t9f3">N=14</footnote>
                                       </td>
                                       <td stylecode="Rrule">2.27 (1.72, 2.99)</td>
                                       <td stylecode="Rrule">--</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" colspan="8">HIV Protease Inhibitor</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" rowspan="2">Atazanavir/ ritonavir</td>
                                       <td stylecode="Rrule">Atazanavir 300 mg/ ritonavir 100 mg once daily</td>
                                       <td stylecode="Rrule">EBR</td>
                                       <td stylecode="Rrule">50 mg once daily</td>
                                       <td stylecode="Rrule">8</td>
                                       <td stylecode="Rrule">1.07 (0.98, 1.17)</td>
                                       <td stylecode="Rrule">1.02 (0.96, 1.08)</td>
                                       <td stylecode="Rrule">1.15 (1.02, 1.29)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">Atazanavir 300 mg/ ritonavir 100 mg once daily</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">200 mg once daily</td>
                                       <td stylecode="Rrule">11</td>
                                       <td stylecode="Rrule">1.43 (1.30, 1.57)</td>
                                       <td stylecode="Rrule">1.12 (1.01, 1.24)</td>
                                       <td stylecode="Rrule">1.23 (1.13, 1.34)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" rowspan="2">Darunavir/ ritonavir</td>
                                       <td stylecode="Rrule">Darunavir 600 mg/ ritonavir 100 mg twice daily</td>
                                       <td stylecode="Rrule">EBR</td>
                                       <td stylecode="Rrule">50 mg once daily</td>
                                       <td stylecode="Rrule">8</td>
                                       <td stylecode="Rrule">0.95 (0.86, 1.06)</td>
                                       <td stylecode="Rrule">0.95 (0.85, 1.05)</td>
                                       <td stylecode="Rrule">0.94 (0.85, 1.05)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">Darunavir 600 mg/ ritonavir 100 mg twice daily</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">200 mg once daily</td>
                                       <td stylecode="Rrule">13</td>
                                       <td stylecode="Rrule">1.11 (0.99, 1.24)</td>
                                       <td stylecode="Rrule">1.10 (0.96, 1.25)</td>
                                       <td stylecode="Rrule">1.00 (0.85, 1.18)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" rowspan="2">Lopinavir/ ritonavir</td>
                                       <td stylecode="Rrule">Lopinavir 400 mg/ ritonavir 100 mg twice daily</td>
                                       <td stylecode="Rrule">EBR</td>
                                       <td stylecode="Rrule">50 mg once daily</td>
                                       <td stylecode="Rrule">9</td>
                                       <td stylecode="Rrule">1.02 (0.93, 1.13)</td>
                                       <td stylecode="Rrule">1.02 (0.92, 1.13)</td>
                                       <td stylecode="Rrule">1.07 (0.97, 1.18)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">Lopinavir 400 mg/ ritonavir 100 mg twice daily</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">200 mg once daily</td>
                                       <td stylecode="Rrule">13</td>
                                       <td stylecode="Rrule">1.03 (0.96, 1.16)</td>
                                       <td stylecode="Rrule">0.97 (0.88, 1.08)</td>
                                       <td stylecode="Rrule">0.97 (0.81, 1.15)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" colspan="8">HIV Integrase Strand Transfer Inhibitor</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Dolutegravir</td>
                                       <td stylecode="Rrule">Dolutegravir 50 mg single-dose</td>
                                       <td stylecode="Rrule">EBR + GZR </td>
                                       <td stylecode="Rrule">50 mg + 200 mg once daily</td>
                                       <td stylecode="Rrule">12</td>
                                       <td stylecode="Rrule">1.16 (1.00, 1.34)</td>
                                       <td stylecode="Rrule">1.22 (1.05, 1.40)</td>
                                       <td stylecode="Rrule">1.14 (0.95, 1.36)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" rowspan="2">Raltegravir</td>
                                       <td stylecode="Rrule">Raltegravir 400 mg single-dose</td>
                                       <td stylecode="Rrule">EBR</td>
                                       <td stylecode="Rrule">50 mg single-dose</td>
                                       <td stylecode="Rrule">10</td>
                                       <td stylecode="Rrule">1.02 (0.81, 1.27)</td>
                                       <td stylecode="Rrule">1.09 (0.83, 1.44)</td>
                                       <td stylecode="Rrule">0.99 (0.80, 1.22)<footnote id="t9f4">C12</footnote>
                                       </td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">Raltegravir 400 mg twice daily</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">200 mg once daily</td>
                                       <td stylecode="Rrule">11</td>
                                       <td stylecode="Rrule">1.43 (0.89, 2.30)</td>
                                       <td stylecode="Rrule">1.46 (0.78, 2.73)</td>
                                       <td stylecode="Rrule">1.47 (1.09, 2.00)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" colspan="8">HIV Non-Nucleoside Reverse Transcriptase Inhibitor</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" rowspan="2">Efavirenz</td>
                                       <td stylecode="Rrule">Efavirenz 600 mg once daily</td>
                                       <td stylecode="Rrule">EBR</td>
                                       <td stylecode="Rrule">50 mg once daily</td>
                                       <td stylecode="Rrule">7</td>
                                       <td stylecode="Rrule">0.82 (0.78, 0.86)</td>
                                       <td stylecode="Rrule">0.74 (0.67, 0.82)</td>
                                       <td stylecode="Rrule">0.91 (0.87, 0.96)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">Efavirenz 600 mg once daily</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">200 mg once daily</td>
                                       <td stylecode="Rrule">11</td>
                                       <td stylecode="Rrule">1.00 (0.96, 1.05)</td>
                                       <td stylecode="Rrule">1.03 (0.99, 1.08)</td>
                                       <td stylecode="Rrule">0.93 (0.88, 0.98)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Rilpivirine</td>
                                       <td stylecode="Rrule">Rilpivirine 25 mg once daily</td>
                                       <td stylecode="Rrule">EBR + GZR </td>
                                       <td stylecode="Rrule">50 mg + 200 mg once daily</td>
                                       <td stylecode="Rrule">19</td>
                                       <td stylecode="Rrule">1.13 (1.07, 1.20)</td>
                                       <td stylecode="Rrule">1.07 (0.97, 1.17)</td>
                                       <td stylecode="Rrule">1.16 (1.09, 1.23)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" colspan="8">HIV Nucleotide Reverse Transcriptase Inhibitor</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" rowspan="2">Tenofovir disoproxil fumarate</td>
                                       <td stylecode="Rrule">Tenofovir disoproxil fumarate 300 mg once daily</td>
                                       <td stylecode="Rrule">EBR</td>
                                       <td stylecode="Rrule">50 mg once daily</td>
                                       <td stylecode="Rrule">10</td>
                                       <td stylecode="Rrule">1.34 (1.23, 1.47)</td>
                                       <td stylecode="Rrule">1.47 (1.32, 1.63)</td>
                                       <td stylecode="Rrule">1.29 (1.18, 1.41)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">Tenofovir disoproxil fumarate 300 mg once daily</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">200 mg once daily</td>
                                       <td stylecode="Rrule">12</td>
                                       <td stylecode="Rrule">1.18 (1.09, 1.28)</td>
                                       <td stylecode="Rrule">1.14 (1.04, 1.25)</td>
                                       <td stylecode="Rrule">1.24 (1.10, 1.39)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" colspan="8">Immunosuppressant</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Cyclosporine</td>
                                       <td stylecode="Rrule">Cyclosporine 400 mg single-dose</td>
                                       <td stylecode="Rrule">EBR + GZR </td>
                                       <td stylecode="Rrule">50 mg + 200 mg once daily</td>
                                       <td stylecode="Rrule">14</td>
                                       <td stylecode="Rrule">0.96 (0.90, 1.02)</td>
                                       <td stylecode="Rrule">0.90 (0.85, 0.97)</td>
                                       <td stylecode="Rrule">1.00 (0.92, 1.08)<footnoteref idref="t9f4"></footnoteref>
                                       </td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Mycophenolic acid</td>
                                       <td stylecode="Rrule">Mycophenolate mofetil 1000 mg single-dose</td>
                                       <td stylecode="Rrule">EBR + GZR </td>
                                       <td stylecode="Rrule">50 mg + 200 mg once daily</td>
                                       <td stylecode="Rrule">14</td>
                                       <td stylecode="Rrule">0.95 (0.87, 1.03)</td>
                                       <td stylecode="Rrule">0.85 (0.67, 1.07)</td>
                                       <td stylecode="Rrule">--</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Prednisolone</td>
                                       <td stylecode="Rrule">Prednisone 40 mg single-dose</td>
                                       <td stylecode="Rrule">EBR + GZR </td>
                                       <td stylecode="Rrule">50 mg + 200 mg once daily</td>
                                       <td stylecode="Rrule">14</td>
                                       <td stylecode="Rrule">1.08 (1.01, 1.16)</td>
                                       <td stylecode="Rrule">1.04 (0.99, 1.09)</td>
                                       <td stylecode="Rrule">--</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Prednisone</td>
                                       <td stylecode="Rrule">Prednisone 40 mg single-dose</td>
                                       <td stylecode="Rrule">EBR + GZR </td>
                                       <td stylecode="Rrule">50 mg + 200 mg once daily</td>
                                       <td stylecode="Rrule">14</td>
                                       <td stylecode="Rrule">1.08 (1.00, 1.17)</td>
                                       <td stylecode="Rrule">1.05 (1.00, 1.10)</td>
                                       <td stylecode="Rrule">--</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Tacrolimus</td>
                                       <td stylecode="Rrule">Tacrolimus<br>2 mg single-dose</td>
                                       <td stylecode="Rrule">EBR + GZR </td>
                                       <td stylecode="Rrule">50 mg + 200 mg once daily</td>
                                       <td stylecode="Rrule">16</td>
                                       <td stylecode="Rrule">1.43 (1.24, 1.64)</td>
                                       <td stylecode="Rrule">0.60 (0.52, 0.69)</td>
                                       <td stylecode="Rrule">1.70 (1.49, 1.94)<footnoteref idref="t9f4"></footnoteref>
                                       </td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" colspan="8">Oral Contraceptive</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" rowspan="2">Ethinyl estradiol (EE)</td>
                                       <td stylecode="Rrule" rowspan="4">0.03 mg EE/ 0.15 mg LNG single-dose</td>
                                       <td stylecode="Rrule">EBR</td>
                                       <td stylecode="Rrule">50 mg once daily</td>
                                       <td stylecode="Rrule">20</td>
                                       <td stylecode="Rrule">1.01 (0.97, 1.05)</td>
                                       <td stylecode="Rrule">1.10 (1.05, 1.16)</td>
                                       <td stylecode="Rrule">--</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">200 mg once daily</td>
                                       <td stylecode="Rrule">20</td>
                                       <td stylecode="Rrule">1.10 (1.05, 1.14)</td>
                                       <td stylecode="Rrule">1.05 (0.98, 1.12)</td>
                                       <td stylecode="Rrule">--</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" rowspan="2">Levonorgestrel (LNG)</td>
                                       <td stylecode="Rrule">EBR</td>
                                       <td stylecode="Rrule">50 mg once daily</td>
                                       <td stylecode="Rrule">20</td>
                                       <td stylecode="Rrule">1.14 (1.04, 1.24)</td>
                                       <td stylecode="Rrule">1.02 (0.95, 1.08)</td>
                                       <td stylecode="Rrule">--</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">200 mg once daily</td>
                                       <td stylecode="Rrule">20</td>
                                       <td stylecode="Rrule">1.23 (1.15, 1.32)</td>
                                       <td stylecode="Rrule">0.93 (0.84, 1.03)</td>
                                       <td stylecode="Rrule">--</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" colspan="8">Opioid Substitution Therapy</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" rowspan="2">Buprenorphine</td>
                                       <td stylecode="Rrule">Buprenorphine 8 mg/Naloxone 2 mg single-dose</td>
                                       <td stylecode="Rrule">EBR</td>
                                       <td stylecode="Rrule">50 mg once daily</td>
                                       <td stylecode="Rrule">15</td>
                                       <td stylecode="Rrule">0.98 (0.89, 1.08)</td>
                                       <td stylecode="Rrule">0.94 (0.82, 1.08)</td>
                                       <td stylecode="Rrule">0.98 (0.88, 1.09)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">Buprenorphine 8-24 mg/ Naloxone 2-6 mg once daily</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">200 mg once daily</td>
                                       <td stylecode="Rrule">12</td>
                                       <td stylecode="Rrule">0.98 (0.81, 1.19)</td>
                                       <td stylecode="Rrule">0.90 (0.76, 1.07)</td>
                                       <td stylecode="Rrule">--</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" rowspan="2">R-Methadone</td>
                                       <td stylecode="Rrule">Methadone 20-120 mg once daily</td>
                                       <td stylecode="Rrule">EBR</td>
                                       <td stylecode="Rrule">50 mg once daily</td>
                                       <td stylecode="Rrule">10</td>
                                       <td stylecode="Rrule">1.03 (0.92, 1.15)</td>
                                       <td stylecode="Rrule">1.07 (0.95, 1.20)</td>
                                       <td stylecode="Rrule">1.10 (0.96, 1.26)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">Methadone 20-150 mg once daily</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">200 mg once daily</td>
                                       <td stylecode="Rrule">12</td>
                                       <td stylecode="Rrule">1.09 (1.02, 1.17)</td>
                                       <td stylecode="Rrule">1.03 (0.96, 1.11)</td>
                                       <td stylecode="Rrule">--</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" rowspan="2">S-Methadone</td>
                                       <td stylecode="Rrule">Methadone 20-120 mg once daily</td>
                                       <td stylecode="Rrule">EBR</td>
                                       <td stylecode="Rrule">50 mg once daily</td>
                                       <td stylecode="Rrule">10</td>
                                       <td stylecode="Rrule">1.09 (0.94, 1.26)</td>
                                       <td stylecode="Rrule">1.09 (0.95, 1.25)</td>
                                       <td stylecode="Rrule">1.20 (0.98, 1.47)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule">Methadone 20-150 mg once daily</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">200 mg once daily</td>
                                       <td stylecode="Rrule">12</td>
                                       <td stylecode="Rrule">1.23 (1.12, 1.35)</td>
                                       <td stylecode="Rrule">1.15 (1.07, 1.25)</td>
                                       <td stylecode="Rrule">--</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule" colspan="8">Statin</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Atorvastatin</td>
                                       <td stylecode="Rrule">Atorvastatin 10 mg single-dose</td>
                                       <td stylecode="Rrule">EBR + GZR </td>
                                       <td stylecode="Rrule">50 mg + 200 mg once daily</td>
                                       <td stylecode="Rrule">16</td>
                                       <td stylecode="Rrule">1.94 (1.63, 2.33)</td>
                                       <td stylecode="Rrule">4.34 (3.10, 6.07)</td>
                                       <td stylecode="Rrule">0.21 (0.17, 0.26)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Pitavastatin</td>
                                       <td stylecode="Rrule">Pitavastatin 1 mg single-dose</td>
                                       <td stylecode="Rrule">GZR</td>
                                       <td stylecode="Rrule">200 mg once daily</td>
                                       <td stylecode="Rrule">9</td>
                                       <td stylecode="Rrule">1.11 (0.91, 1.34)</td>
                                       <td stylecode="Rrule">1.27 (1.07, 1.52)</td>
                                       <td stylecode="Rrule">--</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Lrule Rrule">Pravastatin</td>
                                       <td stylecode="Rrule">Pravastatin 40 mg single-dose</td>
                                       <td stylecode="Rrule">EBR + GZR </td>
                                       <td stylecode="Rrule">50 mg + 200 mg once daily</td>
                                       <td stylecode="Rrule">12</td>
                                       <td stylecode="Rrule">1.33 (1.09, 1.64)<footnote id="t9f5">N=10</footnote>
                                       </td>
                                       <td stylecode="Rrule">1.28 (1.05, 1.55)</td>
                                       <td stylecode="Rrule">--</td>
                                    </tr>
                                    <tr>
                                       <td stylecode="Lrule Rrule">Rosuvastatin</td>
                                       <td stylecode="Rrule">Rosuvastatin 10 mg single-dose</td>
                                       <td stylecode="Rrule">EBR + GZR </td>
                                       <td stylecode="Rrule">50 mg + 200 mg once daily</td>
                                       <td stylecode="Rrule">12</td>
                                       <td stylecode="Rrule">2.26 (1.89, 2.69)<footnote id="t9f6">N=8</footnote>
                                       </td>
                                       <td stylecode="Rrule">5.49 (4.29, 7.04)</td>
                                       <td stylecode="Rrule">0.98 (0.84, 1.13)</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text></div>
<span id="ZEPATIER_collapsableElement_12_4" class="safetySubheading">12.4	Microbiology</span><div id="49489-8" class="safetySubdescription"></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Mechanism of Action</content>
                              </p>
                              <p>ZEPATIER combines two direct-acting antiviral agents with distinct mechanisms of action and non-overlapping resistance profiles to target HCV at multiple steps in the viral lifecycle.</p>
                              <p>Elbasvir is an inhibitor of HCV NS5A, which is essential for viral RNA replication and virion assembly. The mechanism of action of elbasvir has been characterized based on cell culture antiviral activity and drug resistance mapping studies.</p>
                              <p>Grazoprevir is an inhibitor of the HCV NS3/4A protease which is necessary for the proteolytic cleavage of the HCV encoded polyprotein (into mature forms of the NS3, NS4A, NS4B, NS5A, and NS5B proteins) and is essential for viral replication. In a biochemical assay, grazoprevir inhibited the proteolytic activity of the recombinant HCV genotype 1a, 1b, and 4a NS3/4A protease enzymes with IC<sub>50</sub> values of 7 pM, 4 pM, and 62 pM, respectively. </p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Antiviral Activity </content>
                              </p>
                              <p>In HCV replicon assays, the EC<sub>50</sub> values of elbasvir against full-length replicons from genotypes 1a, 1b, and 4, were 4 pM, 3 pM, and 0.3 pM, respectively. The median EC<sub>50</sub> values of elbasvir against chimeric replicons encoding NS5A sequences from clinical isolates were 5 pM for genotype 1a (range 3-9 pM; N=5), 9 pM for genotype 1b (range 5-10 pM; N=4), 0.2 pM for genotype 4a (range 0.2-0.2 pM; N=2), 3,600 pM for genotype 4b (range 17 pM-34,000 pM; N=3), 0.45 pM for genotype 4d (range 0.4-0.5 pM; N=2), 1.9 pM for genotype 4f (N=1), 36.3 pM for genotype 4g (range 0.6-72 pM; N=2), 0.6 pM for genotype 4m (range 0.4-0.7 pM; N=2), 2.2 pM for genotype 4o (N=1), and 0.5 pM for genotype 4q (N=1).</p>
                              <p>In HCV replicon assays, the EC<sub>50</sub> values of grazoprevir against full-length replicons from genotypes 1a, 1b, and 4, were 0.4 nM, 0.5 nM, and 0.3 nM, respectively. The median EC<sub>50</sub> values of grazoprevir against chimeric replicons encoding NS3/4A sequences from clinical isolates were 0.8 nM for genotype 1a (range 0.4-5.1 nM; N=10), 0.3 nM for genotype 1b (range 0.2-5.9 nM; N=9), 0.3 nM for genotype 4a (N=1), 0.16 nM for genotype 4b (range 0.11-0.2 nM; N=2), and 0.24 nM for genotype 4g (range 0.15-0.33 nM; N=2). </p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Combination Antiviral Activity</content>
                              </p>
                              <p>Evaluation of elbasvir in combination with grazoprevir or ribavirin showed no antagonistic effect in reducing HCV RNA levels in replicon cells. Evaluation of grazoprevir in combination with ribavirin showed no antagonistic effect in reducing HCV RNA levels in replicon cells. </p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Resistance</content>
                              </p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Persistence of Resistance-Associated Substitutions</content>
                              </p>
                              <p>The persistence of elbasvir and grazoprevir treatment-emergent amino acid substitutions in NS5A, and NS3, respectively, was assessed in HCV genotype 1-infected subjects in Phase 2 and 3 trials whose virus had treatment-emergent resistance-associated substitutions in the drug target, and with available data through at least 24 weeks post-treatment using population nucleotide sequence analysis. </p>
                              <p>Viral populations with treatment-emergent NS5A resistance-associated substitutions were generally more persistent than those with NS3 resistance-associated substitutions. Among genotype 1a-infected subjects, NS5A resistance-associated substitutions persisted at detectable levels at follow-up week 12 in 95% (35/37) of subjects and in 100% (9/9) of subjects with follow-up week 24 data. Among genotype 1b-infected subjects, NS5A resistance-associated substitutions persisted at detectable levels in 100% (7/7) of subjects at follow-up week 12 and in 100% (3/3) of subjects with follow-up week 24 data.</p>
                              <p>Among genotype 1a-infected subjects, NS3 resistance-associated substitutions persisted at detectable levels at follow-up week 24 in 31% (4/13) of subjects. Among genotype 1b-infected subjects, NS3 resistance-associated substitutions persisted at detectable levels at follow-up week 24 in 50% (1/2) of subjects.</p>
                              <p>Due to the limited number of genotype 4-infected subjects with treatment-emergent NS5A and NS3 resistance-associated substitutions, trends in persistence of treatment-emergent substitutions in this genotype could not be established. </p>
                              <p>The lack of detection of a virus containing a resistance-associated substitution does not necessarily indicate that viral populations carrying that substitution have declined to a background level that may have existed prior to treatment. The long-term clinical impact of the emergence or persistence of virus containing ZEPATIER-resistance-associated substitutions is unknown.</p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Effect of Baseline HCV Amino Acid Polymorphisms on Treatment Response in Genotype 1-Infected Subjects </content>
                              </p>
                              <p>Analyses using population nucleotide sequencing were conducted to explore the association between NS5A or NS3 amino acid polymorphisms and treatment response among treatment-naïve and treatment-experienced genotype 1-infected subjects. Baseline NS5A polymorphisms at resistance-associated positions (focusing on any change from subtype reference at NS5A amino acid positions 28, 30, 31, or 93) were evaluated. Baseline NS3 polymorphisms at positions 36, 54, 55, 56, 80, 107, 122, 132, 155, 156, 158, 168, 170, or 175 were evaluated. Analyses of SVR12 rates pooled data from subjects naïve to direct-acting antivirals and who received ZEPATIER with or without ribavirin in Phase 3 clinical trials, and censored subjects who did not achieve SVR12 for reasons unrelated to virologic failure.</p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Effect of Baseline HCV Polymorphisms on Treatment Response in Genotype 4-Infected Subjects</content>
                              </p>
                              <p>Phylogenetic analysis of HCV sequences from genotype 4-infected subjects (n=71) in the pooled analyses of subjects (non-virologic failure-censored) treated with regimens containing ZEPATIER or elbasvir + grazoprevir with or without ribavirin in Phase 2 and 3 clinical trials identified 4 HCV genotype 4 subtypes (4a, 4d, 4k, 4o). Most subjects were infected with either subtype 4a (42%) or 4d (51%); 1 to 2 subjects were infected with each of the other genotype 4 subtypes. Among subjects enrolled at U.S. study sites, 11/13 (85%) were infected with HCV subtype 4a. There were two subjects infected with HCV subtype 4d who experienced virologic failure with the regimen containing grazoprevir and elbasvir. </p>
                              <p>In genotype 4-infected subjects, SVR12 rates for subjects with baseline NS5A polymorphisms (any change from reference at NS5A amino acid positions 28, 30, 31, 58, and 93 by population nucleotide sequencing) were 100% (28/28) and for subjects without baseline NS5A polymorphisms were 95% (41/43). </p>
                              <p>In genotype 4-infected subjects, SVR12 rates for subjects with baseline NS3 polymorphisms (any change from reference at NS3 amino acid positions 36, 54, 55, 56, 80, 107, 122, 132, 155, 156, 158, 168, 170, and 175 by population nucleotide sequencing) were 100% (18/18) and for subjects without baseline NS3 polymorphisms were 96% (51/53). </p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Cross Resistance </content>
                              </p>
                              <p>Cross resistance is possible among NS5A inhibitors and NS3/4A protease inhibitors by class. Elbasvir and grazoprevir are fully active against viral populations with substitutions conferring resistance to NS5B inhibitors. </p>
                              <p>In the C-SALVAGE trial, subjects with genotype 1 infection who had failed prior treatment with boceprevir (n=28), simeprevir (n=8), or telaprevir (n=43) in combination with PegIFN + RBV received EBR 50 mg once daily + GZR 100 mg once daily + RBV for 12 weeks. There are limited data to determine the impact of HCV NS3 resistance-associated substitutions detected at baseline in treatment-experienced subjects who failed prior PegIFN + RBV + HCV protease inhibitor therapy and received ZEPATIER with ribavirin. SVR was achieved in 88% (21/24) of genotype 1a and genotype 1b infected subjects with NS3 resistance-associated substitutions detected at baseline. Specific NS3 substitutions observed at baseline included one or more of the following: V36L/M (n=8), T54S (n=4), S122G/T (n=9), R155K/T (n=9), A156S/T (n=1), and D168E/N (n=3). SVR was 100% (55/55) in subjects without baseline NS3 resistance substitutions. The 3 virologic failure subjects had the following NS3 or NS5A substitutions/polymorphisms at baseline: NS3 R155T/D168N, NS3 R155K plus NS5A H58D, and NS3 T54S plus NS5A L31M.</p>
                              <p>The efficacy of ZEPATIER has not been established in patients who have previously failed treatment with other regimens that included an NS5A inhibitor. </p>
                           </text></div>
</div>
</div>
<div class="section">
<div id="nonCollapsableElement_43680-8">
<div class="drugSubheadings">
<span id="ZEPATIER_43680-8" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>13 NONCLINICAL TOXICOLOGY</div>
<div id="ZEPATIER_previewText_43680-8" class="previewText"><span>...</span></div>
</div>
<div id="ZEPATIER_collapsableElement_43680-8" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText"></div>
<span id="ZEPATIER_collapsableElement_13_1" class="safetySubheading">13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</span><div id="34083-6" class="safetySubdescription"></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Carcinogenesis and Mutagenesis </content>
                              </p>
                              <p>Elbasvir and grazoprevir were not genotoxic in a battery of <content stylecode="italics">in vitro</content> or <content stylecode="italics">in vivo</content> assays, including microbial mutagenesis, chromosomal aberration in Chinese Hamster Ovary cells, and in <content stylecode="italics">in vivo</content> rat micronucleus assays. </p>
                              <p>Carcinogenicity studies with elbasvir or grazoprevir have not been conducted.</p>
                              <p>If ZEPATIER is administered in a regimen containing ribavirin, the information for ribavirin on carcinogenesis and mutagenesis also applies to this combination regimen. Refer to the ribavirin prescribing information for information on carcinogenesis and mutagenesis.</p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Impairment of Fertility </content>
                              </p>
                              <p>No effects on mating, female or male fertility, or early embryonic development were observed in rats at up to the highest dose tested. Systemic exposures (AUC) to elbasvir and grazoprevir were approximately 8 and 114 times, respectively, the exposure in humans at the recommended human dose. </p>
                              <p>If ZEPATIER is administered with ribavirin, the information for ribavirin on impairment of fertility also applies to this combination regimen. Refer to the ribavirin prescribing information for information on impairment of fertility.</p>
                           </text></div>
</div>
</div>
<div class="section">
<div id="nonCollapsableElement_34092-7">
<div class="drugSubheadings">
<span id="ZEPATIER_34092-7" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>14 CLINICAL STUDIES</div>
<div id="ZEPATIER_previewText_34092-7" class="previewText"><span>...</span></div>
</div>
<div id="ZEPATIER_collapsableElement_34092-7" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText"></div>
<span id="ZEPATIER_collapsableElement_14_1" class="safetySubheading">14.1	Overview of Clinical Trials </span><div id="42229-5" class="safetySubdescription"><text>
                        <p>The efficacy of ZEPATIER was assessed in 2 placebo-controlled trials and 4 uncontrolled Phase 2 and 3 clinical trials in 1401 subjects with genotype (GT) 1, 4, or 6 chronic hepatitis C virus infection with compensated liver disease (with or without cirrhosis). An overview of the 6 trials (n=1373) contributing to the assessment of efficacy in genotype 1 or 4 is provided in <a href="#t12">Table 12</a>. C-EDGE TN, C-EDGE COINFECTION, C-SCAPE, and C-EDGE TE also included subjects with genotype 6 HCV infection (n=28). Because ZEPATIER is not indicated for genotype 6 infection, results in patients with genotype 6 infection are not included in Clinical Studies (14).</p>
                        <table width="80%" id="t12">
                           <caption>Table 12: Trials Conducted with ZEPATIER</caption>
                           <colgroup><col width="20%" align="left" valign="top">
                           <col width="30%" align="center" valign="top">
                           <col width="50%" align="left" valign="top">
                           </colgroup><thead>
                              <tr>
                                 <th stylecode="Lrule Rrule">Trial</th>
                                 <th stylecode="Rrule">Population</th>
                                 <th stylecode="Rrule" align="center">Study Groups and Duration<br>(Number of Subjects Treated)</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td align="left" valign="top" colspan="3">GT = Genotype</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" colspan="3">TN = Treatment-Naïve</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" colspan="3">TE = Treatment-Experienced (failed prior treatment with interferon [IFN] or peginterferon alfa [PegIFN] with or without ribavirin [RBV] or were intolerant to prior therapy).</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">C-EDGE TN<br>(double-blind)</td>
                                 <td stylecode="Rrule">GT 1, 4<br>TN with or without cirrhosis</td>
                                 <td stylecode="Rrule">
                                    <ul ultype="unordered" stylecode="Disc">
                                       <li>ZEPATIER for 12 weeks (N=306)</li>
                                       <li>Placebo for 12 weeks (N=102)</li>
                                    </ul>
                                 </td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">C-EDGE COINFECTION<br>(open-label)</td>
                                 <td stylecode="Rrule">GT 1, 4<br>TN with or without cirrhosis<br>HCV/HIV-1 co-infection</td>
                                 <td stylecode="Rrule">
                                    <ul ultype="unordered" stylecode="Disc">
                                       <li>ZEPATIER for 12 weeks (N=217)</li>
                                    </ul>
                                 </td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">C-SURFER<br>(double-blind)</td>
                                 <td stylecode="Rrule">GT 1<br>TN or TE with or without cirrhosis<br>Severe Renal Impairment including Hemodialysis</td>
                                 <td stylecode="Rrule">
                                    <ul ultype="unordered" stylecode="Disc">
                                       <li>EBR<footnote id="t12f1">EBR = elbasvir 50 mg; GZR = grazoprevir 100 mg; EBR + GZR = co-administered as single agents.</footnote> + GZR<footnoteref idref="t12f1"></footnoteref> for 12 weeks (N=122)</li>
                                       <li>Placebo for 12 weeks (N=113)</li>
                                    </ul>
                                 </td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">C-SCAPE<br>(open-label)</td>
                                 <td stylecode="Rrule">GT 4<br>TN without cirrhosis</td>
                                 <td stylecode="Rrule">
                                    <ul ultype="unordered" stylecode="Disc">
                                       <li>EBR<footnoteref idref="t12f1"></footnoteref> + GZR<footnoteref idref="t12f1"></footnoteref> for 12 weeks (N=10)</li>
                                       <li>EBR<footnoteref idref="t12f1"></footnoteref> + GZR<footnoteref idref="t12f1"></footnoteref> + RBV for 12 weeks (N=10)</li>
                                    </ul>
                                 </td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">C-EDGE TE<br>(open-label)</td>
                                 <td stylecode="Rrule">GT 1, 4<br>TE with or without cirrhosis<br>HCV/HIV-1 co-infection</td>
                                 <td stylecode="Rrule">
                                    <ul ultype="unordered" stylecode="Disc">
                                       <li>ZEPATIER for 12 or 16 weeks (N=105, and 101, respectively)</li>
                                       <li>ZEPATIER + RBV for 12 or 16 weeks (N=104 and 104, respectively)</li>
                                    </ul>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Lrule Rrule">C-SALVAGE<br>(open-label)</td>
                                 <td stylecode="Rrule">GT 1<br>TE with HCV protease inhibitor regimen<footnote id="t12f2">Failed prior treatment with boceprevir, telaprevir, or simeprevir in combination with PegIFN + RBV.</footnote> with or without cirrhosis</td>
                                 <td stylecode="Rrule">
                                    <ul ultype="unordered" stylecode="Disc">
                                       <li>EBR<footnoteref idref="t12f1"></footnoteref> + GZR<footnoteref idref="t12f1"></footnoteref> + RBV for 12 weeks (N=79)</li>
                                    </ul>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <p>ZEPATIER was administered once daily by mouth in these trials. For subjects who received ribavirin (RBV), the RBV dosage was weight-based (less than 66 kg = 800 mg per day, 66 to 80 kg = 1000 mg per day, 81 to 105 kg = 1200 mg per day, greater than 105 kg = 1400 mg per day) administered by mouth in two divided doses with food. </p>
                        <p>Sustained virologic response (SVR) was the primary endpoint in all trials and was defined as HCV RNA less than lower limit of quantification (LLOQ) at 12 weeks after the cessation of treatment (SVR12). Serum HCV RNA values were measured during these clinical trials using the COBAS AmpliPrep/COBAS Taqman HCV test (version 2.0) with an LLOQ of 15 HCV RNA IU per mL, with the exception of C-SCAPE where the assay had an LLOQ of 25 HCV RNA IU per mL.</p>
                     </text></div>
<span id="ZEPATIER_collapsableElement_14_2" class="safetySubheading">14.2	Clinical Trials in Treatment-Naïve Subjects with Genotype 1 HCV (C-EDGE TN and C-EDGE COINFECTION)</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>The efficacy of ZEPATIER in treatment-naïve subjects with genotype 1 chronic hepatitis C virus infection with or without cirrhosis was demonstrated in the C-EDGE TN and C-EDGE COINFECTION trials. </p>
                        <p>C-EDGE TN was a randomized, double-blind, placebo-controlled trial in treatment-naïve subjects with genotype 1 or 4 infection with or without cirrhosis. Subjects were randomized in a 3:1 ratio to: ZEPATIER for 12 weeks (immediate treatment group) or placebo for 12 weeks followed by open-label treatment with ZEPATIER for 12 weeks (deferred treatment group). Among subjects with genotype 1 infection randomized to the immediate treatment group, the median age was 55 years (range: 20 to 78); 56% of the subjects were male; 61% were White; 20% were Black or African American; 8% were Hispanic or Latino; mean body mass index was 26 kg/m<sup>2</sup>; 72% had baseline HCV RNA levels greater than 800,000 IU per mL; 24% had cirrhosis; 67% had non-C/C IL28B alleles (CT or TT); and 55% had genotype 1a and 45% had genotype 1b chronic HCV infection. </p>
                        <p>C-EDGE COINFECTION was an open-label, single-arm trial in treatment-naïve HCV/HIV-1 co-infected subjects with genotype 1 or 4 infection with or without cirrhosis. Subjects received ZEPATIER for 12 weeks. Among subjects with genotype 1 infection, the median age was 50 years (range: 21 to 71); 85% of the subjects were male; 75% were White; 19% were Black or African American; 6% were Hispanic or Latino; mean body mass index was 25 kg per m<sup>2</sup>; 59% had baseline HCV RNA levels greater than 800,000 IU per mL; 16% had cirrhosis; 65% had non-C/C IL28B alleles (CT or TT); and 76% had genotype 1a, 23% had genotype 1b, and 1% had genotype 1-Other chronic HCV infection. </p>
                        <p>
                           <a href="#t13">Table 13</a> presents treatment outcomes for ZEPATIER in treatment-naïve subjects with genotype 1 infection from C-EDGE TN (immediate treatment group) and C-EDGE COINFECTION. For treatment outcomes for ZEPATIER in genotype 4 infection, <content stylecode="italics">[see <a href="#S14.5">Clinical Studies (14.5)</a>]</content>.</p>
                        <table width="75%" id="t13">
                           <caption>Table 13: C-EDGE TN and C-EDGE COINFECTION: SVR12 in Treatment-Naïve Subjects with or without Cirrhosis with Genotype 1 HCV Treated with ZEPATIER for 12 Weeks</caption>
                           <colgroup><col width="46%" align="left" valign="bottom">
                           <col width="27%" align="center" valign="bottom">
                           <col width="27%" align="center" valign="bottom">
                           </colgroup><thead>
                              <tr stylecode="Botrule">
                                 <th stylecode="Rrule Lrule" align="center" valign="top">Trial</th>
                                 <th stylecode="Rrule" valign="top">C-EDGE TN<br>(Immediate Treatment Group)</th>
                                 <th stylecode="Rrule" valign="top">C-EDGE<br>COINFECTION<br>(HCV/HIV-1<br>Co-Infection)</th>
                              </tr>
                              <tr>
                                 <th stylecode="Rrule Lrule" align="center" valign="top">Regimen</th>
                                 <th stylecode="Rrule" valign="top">ZEPATIER<br>12 Weeks<br>N=288</th>
                                 <th stylecode="Rrule" valign="top">ZEPATIER<br>12 Weeks<br>N=189</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr stylecode="Botrule">
                                 <td stylecode="Rrule Lrule">SVR in Genotype 1 </td>
                                 <td stylecode="Rrule">95% (273/288)</td>
                                 <td stylecode="Rrule">95% (179/189)</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Rrule Lrule" colspan="3" align="left">Outcome for subjects without SVR</td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule Lrule">&nbsp;&nbsp;On-treatment Virologic Failure<footnote>Includes subjects with virologic breakthrough.</footnote>
                                 </td>
                                 <td stylecode="Rrule">&lt;1% (1/288)</td>
                                 <td stylecode="Rrule">0% (0/189)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule Lrule">&nbsp;&nbsp;Relapse</td>
                                 <td stylecode="Rrule">3% (10/288)</td>
                                 <td stylecode="Rrule">3% (6/189)</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Rrule Lrule">&nbsp;&nbsp;Other<footnote>Other includes subjects who discontinued due to adverse event, lost to follow-up, or subject withdrawal.</footnote>
                                 </td>
                                 <td stylecode="Rrule">1% (4/288)</td>
                                 <td stylecode="Rrule">2% (4/189)</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Rrule Lrule" colspan="3" align="left">SVR by Genotype 1 Subtypes</td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule Lrule">&nbsp;&nbsp;GT 1a<footnote>For the impact of baseline NS5A polymorphisms on SVR12, <content stylecode="italics">[see <a href="#S12.4">Microbiology (12.4)</a>], <a href="#t11">Table 11</a>
                                       </content>.</footnote>
                                 </td>
                                 <td stylecode="Rrule">92% (144/157)</td>
                                 <td stylecode="Rrule">94% (136/144)</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Rrule Lrule">&nbsp;&nbsp;GT 1b<footnote>Includes genotype 1 subtypes other than 1a or 1b.</footnote>
                                 </td>
                                 <td stylecode="Rrule">98% (129/131)</td>
                                 <td stylecode="Rrule">96% (43/45)</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Rrule Lrule" colspan="3" align="left">SVR by Cirrhosis status</td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule Lrule">&nbsp;&nbsp;Non-cirrhotic</td>
                                 <td stylecode="Rrule">94% (207/220)</td>
                                 <td stylecode="Rrule">94% (148/158)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule Lrule">&nbsp;&nbsp;Cirrhotic</td>
                                 <td stylecode="Rrule">97% (66/68)</td>
                                 <td stylecode="Rrule">100% (31/31)</td>
                              </tr>
                           </tbody>
                        </table>
                     </text></div>
<span id="ZEPATIER_collapsableElement_14_3" class="safetySubheading">14.3	Clinical Trials in Treatment-Experienced Subjects with Genotype 1 HCV </span><div id="42229-5" class="safetySubdescription"></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Treatment-Experienced Subjects who Failed Prior PegIFN with RBV Therapy (C-EDGE TE)</content>
                              </p>
                              <p>C-EDGE TE was a randomized, open-label comparative trial in subjects with genotype 1 or 4 infection, with or without cirrhosis, with or without HCV/HIV-1 co-infection, who had failed prior therapy with PegIFN + RBV therapy. Subjects were randomized in a 1:1:1:1 ratio to one of the following treatment groups: ZEPATIER for 12 weeks, ZEPATIER + RBV for 12 weeks, ZEPATIER for 16 weeks, or ZEPATIER + RBV for 16 weeks. Among subjects with genotype 1 infection, the median age was 57 years (range: 19 to 77); 64% of the subjects were male; 67% were White; 18% were Black or African American; 9% were Hispanic or Latino; mean body mass index was 28 kg/m<sup>2</sup>; 78% had baseline HCV RNA levels greater than 800,000 IU/mL; 34% had cirrhosis; 79% had non-C/C IL28B alleles (CT or TT); and 60% had genotype 1a, 39% had genotype 1b, and 1% had genotype 1-Other chronic HCV infection.</p>
                              <p>Treatment outcomes in genotype 1 subjects treated with ZEPATIER for 12 weeks or ZEPATIER with RBV for 16 weeks are presented in <a href="#t14">Table 14</a>. Treatment outcomes with ZEPATIER with RBV for 12 weeks or without RBV for 16 weeks are not shown because these regimens are not recommended in PegIFN/RBV-experienced genotype 1 patients. For treatment outcomes for ZEPATIER in genotype 4 infection, <content stylecode="italics">[see <a href="#S14.5">Clinical Studies (14.5)</a>]</content>.</p>
                              <table width="75%" id="t14">
                                 <caption>Table 14: C-EDGE TE: SVR12 in Treatment-Experienced Subjects who Failed Prior PegIFN with RBV with or without Cirrhosis, with or without HCV/HIV-1 Co-infection with Genotype 1 HCV Treated with ZEPATIER for 12 Weeks or ZEPATIER with Ribavirin for 16 Weeks</caption>
                                 <colgroup><col width="46%" align="left" valign="bottom">
                                 <col width="27%" align="center" valign="bottom">
                                 <col width="27%" align="center" valign="bottom">
                                 </colgroup><thead>
                                    <tr>
                                       <th stylecode="Rrule Lrule" align="center" valign="top">Regimen</th>
                                       <th stylecode="Rrule" valign="top">ZEPATIER<br>12 weeks<br>N=96</th>
                                       <th stylecode="Rrule" valign="top">ZEPATIER + RBV<br>16 weeks<br>N=96</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule Lrule">SVR in Genotype 1 </td>
                                       <td stylecode="Rrule">94% (90/96)</td>
                                       <td stylecode="Rrule">97% (93/96)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule Lrule" colspan="3" align="left">Outcome for subjects without SVR</td>
                                    </tr>
                                    <tr>
                                       <td stylecode="Rrule Lrule">&nbsp;&nbsp;On-treatment Virologic Failure<footnote>Includes subjects with virologic breakthrough or rebound.</footnote>
                                       </td>
                                       <td stylecode="Rrule">0% (0/96)</td>
                                       <td stylecode="Rrule">0% (0/96)</td>
                                    </tr>
                                    <tr>
                                       <td stylecode="Rrule Lrule">&nbsp;&nbsp;Relapse</td>
                                       <td stylecode="Rrule">5% (5/96)</td>
                                       <td stylecode="Rrule">0% (0/96)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule Lrule">&nbsp;&nbsp;Other<footnote>Other includes subjects who discontinued due to adverse event, lost to follow-up, or subject withdrawal.</footnote>
                                       </td>
                                       <td stylecode="Rrule">1% (1/96)</td>
                                       <td stylecode="Rrule">3% (3/96)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule Lrule" colspan="3" align="left">SVR by Genotype 1 Subtypes</td>
                                    </tr>
                                    <tr>
                                       <td stylecode="Rrule Lrule">&nbsp;&nbsp;GT 1a<footnote>For the impact of baseline NS5A polymorphisms on SVR, <content stylecode="italics">[see <a href="#S12.4">Microbiology (12.4)</a>], <a href="#t11">Table 11</a>
                                             </content>.</footnote>
                                       </td>
                                       <td stylecode="Rrule">90% (55/61)</td>
                                       <td stylecode="Rrule">95% (55/58)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule Lrule">&nbsp;&nbsp;GT 1b<footnote>Includes genotype 1 subtypes other than 1a or 1b.</footnote>
                                       </td>
                                       <td stylecode="Rrule">100% (35/35)</td>
                                       <td stylecode="Rrule">100% (38/38)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule Lrule" colspan="3" align="left">SVR by Cirrhosis status</td>
                                    </tr>
                                    <tr>
                                       <td stylecode="Rrule Lrule">&nbsp;&nbsp;Non-cirrhotic</td>
                                       <td stylecode="Rrule">94% (61/65)</td>
                                       <td stylecode="Rrule">95% (61/64)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule Lrule">&nbsp;&nbsp;Cirrhotic</td>
                                       <td stylecode="Rrule">94% (29/31)</td>
                                       <td stylecode="Rrule">100% (32/32)</td>
                                    </tr>
                                    <tr stylecode="Botrule">
                                       <td stylecode="Rrule Lrule" colspan="3" align="left">SVR by Response to Prior HCV Therapy</td>
                                    </tr>
                                    <tr>
                                       <td stylecode="Rrule Lrule">&nbsp;&nbsp;On-treatment Virologic Failure<footnote>Includes prior null responders and partial responders. </footnote>
                                       </td>
                                       <td stylecode="Rrule">90% (57/63)</td>
                                       <td stylecode="Rrule">95% (58/61)</td>
                                    </tr>
                                    <tr>
                                       <td stylecode="Rrule Lrule">&nbsp;&nbsp;Relapser</td>
                                       <td stylecode="Rrule">100% (33/33)</td>
                                       <td stylecode="Rrule">100% (35/35)</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;"></span><div><text>
                              <p>
                                 <content stylecode="underline">Treatment-Experienced Subjects who Failed Prior PegIFN + RBV + HCV Protease Inhibitor Therapy (C-SALVAGE)</content>
                              </p>
                              <p>C-SALVAGE was an open-label single-arm trial in subjects with genotype 1 infection, with or without cirrhosis, who had failed prior treatment with boceprevir, simeprevir, or telaprevir in combination with pegIFN + RBV. Subjects received EBR 50 mg once daily + GZR 100 mg once daily + RBV for 12 weeks. Subjects had a median age of 55 years (range: 23 to 75); 58% of the subjects were male; 97% were White; 3% were Black or African American; 15% were Hispanic or Latino; mean body mass index was 28 kg/m<sup>2</sup>; 63% had baseline HCV RNA levels greater than 800,000 IU/mL; 43% had cirrhosis; and 97% had non-C/C IL28B alleles (CT or TT); 46% had baseline NS3 resistance-associated substitutions.</p>
                              <p>Overall SVR was achieved in 96% (76/79) of subjects receiving EBR + GZR + RBV for 12 weeks. Four percent (3/79) of subjects did not achieve SVR due to relapse. Treatment outcomes were consistent in genotype 1a and genotype 1b subjects, in subjects with different response to previous HCV therapy, and in subjects with or without cirrhosis. Treatment outcomes were generally consistent in subjects with or without NS3 resistance-associated substitutions at baseline, although limited data are available for subjects with specific NS3 resistance-associated substitutions <content stylecode="italics">[see <a href="#S12.4">Microbiology (12.4)</a>]</content>.</p>
                           </text></div>
<span id="ZEPATIER_collapsableElement_14_4" class="safetySubheading">14.4	Clinical Trial in Subjects with Genotype 1 HCV and Severe Renal Impairment including Subjects on Hemodialysis (C-SURFER)</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>C-SURFER was a randomized, double-blind, placebo-controlled trial in subjects with genotype 1 infection, with or without cirrhosis, with chronic kidney disease (CKD) Stage 4 (eGFR 15-29 mL/min/1.73 m<sup>2</sup>) or CKD Stage 5 (eGFR &lt;15 mL/min/1.73 m<sup>2</sup>), including subjects on hemodialysis, who were treatment-naïve or who had failed prior therapy with IFN or PegIFN ± RBV therapy. Subjects were randomized in a 1:1 ratio to one of the following treatment groups: EBR 50 mg once daily + GZR 100 mg once daily for 12 weeks (immediate treatment group) or placebo for 12 weeks followed by open-label treatment with EBR + GZR for 12 weeks (deferred treatment group). In addition, 11 subjects received open-label EBR + GZR for 12 weeks (intensive pharmacokinetic [PK] group). Subjects randomized to the immediate treatment group and intensive PK group had a median age of 58 years (range: 31 to 76); 75% of the subjects were male; 50% were White; 45% were Black or African American; 11% were Hispanic or Latino; 57% had baseline HCV RNA levels greater than 800,000 IU/mL; 6% had cirrhosis; and 72% had non-C/C IL28B alleles (CT or TT).</p>
                        <p>Treatment outcomes in subjects treated with ZEPATIER for 12 weeks in the pooled immediate treatment group and intensive PK group are presented in <a href="#t15">Table 15</a>.</p>
                        <table width="75%" id="t15">
                           <caption>Table 15: C-SURFER: SVR12 in Subjects with Severe Renal Impairment including Subjects on Hemodialysis who were Treatment-Naïve or had Failed Prior IFN or PegIFN ± RBV, with or without Cirrhosis, with Genotype 1 HCV Treated with ZEPATIER for 12 Weeks</caption>
                           <colgroup><col width="50%" align="left" valign="bottom">
                           <col width="50%" align="center" valign="bottom">
                           </colgroup><thead>
                              <tr>
                                 <th stylecode="Lrule Rrule" align="center" valign="top">Regimen</th>
                                 <th stylecode="Rrule" valign="top">EBR + GZR<br>12 weeks<br>(Immediate Treatment Group)<br>N=122<footnote>Includes subjects (n=11) in the intensive PK group. </footnote>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">Overall SVR</td>
                                 <td stylecode="Rrule">94% (115/122)<footnote>SVR was achieved in 99% (115/116) of subjects in the pre-specified primary analysis population, which excluded subjects not receiving at least one dose of study treatment and those with missing data due to death or early study discontinuation for reasons unrelated to treatment response.</footnote>
                                 </td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule" colspan="2" align="left" valign="bottom">Outcome for subjects without SVR</td>
                              </tr>
                              <tr>
                                 <td stylecode="Lrule Rrule">&nbsp;&nbsp;On-treatment Virologic Failure</td>
                                 <td stylecode="Rrule">0% (0/122)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Lrule Rrule">&nbsp;&nbsp;Relapse</td>
                                 <td stylecode="Rrule">&lt;1% (1/122)</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">&nbsp;&nbsp;Other<footnote>Other includes subjects who discontinued due to adverse event, lost to follow-up, or subject withdrawal.</footnote>
                                 </td>
                                 <td stylecode="Rrule">5% (6/122)</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule" colspan="2" align="left" valign="bottom">SVR by Genotype</td>
                              </tr>
                              <tr>
                                 <td stylecode="Lrule Rrule">&nbsp;&nbsp;GT 1a</td>
                                 <td stylecode="Rrule">97% (61/63)</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">&nbsp;&nbsp;GT 1b<footnote>Includes genotype 1 subtypes other than 1a or 1b.</footnote>
                                 </td>
                                 <td stylecode="Rrule">92% (54/59)</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule" colspan="2" align="left" valign="bottom">SVR by Cirrhosis status</td>
                              </tr>
                              <tr>
                                 <td stylecode="Lrule Rrule">&nbsp;&nbsp;No</td>
                                 <td stylecode="Rrule">95% (109/115)</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">&nbsp;&nbsp;Yes</td>
                                 <td stylecode="Rrule">86% (6/7)</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule" colspan="2" align="left" valign="bottom">SVR by Prior HCV Treatment Status</td>
                              </tr>
                              <tr>
                                 <td stylecode="Lrule Rrule">&nbsp;&nbsp;Treatment-naïve</td>
                                 <td stylecode="Rrule">95% (96/101)</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">&nbsp;&nbsp;Treatment-experienced</td>
                                 <td stylecode="Rrule">90% (19/21)</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule" colspan="2" align="left" valign="bottom">SVR by Dialysis Status</td>
                              </tr>
                              <tr>
                                 <td stylecode="Lrule Rrule">&nbsp;&nbsp;No</td>
                                 <td stylecode="Rrule">97% (29/30)</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule">&nbsp;&nbsp;Yes</td>
                                 <td stylecode="Rrule">93% (86/92)</td>
                              </tr>
                              <tr stylecode="Botrule">
                                 <td stylecode="Lrule Rrule" colspan="2" align="left" valign="bottom">SVR by Chronic Kidney Disease Stage</td>
                              </tr>
                              <tr>
                                 <td stylecode="Lrule Rrule">&nbsp;&nbsp;Stage 4</td>
                                 <td stylecode="Rrule">100% (22/22)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Lrule Rrule">&nbsp;&nbsp;Stage 5</td>
                                 <td stylecode="Rrule">93% (93/100)</td>
                              </tr>
                           </tbody>
                        </table>
                     </text></div>
<span id="ZEPATIER_collapsableElement_14_5" class="safetySubheading">14.5	Clinical Trials with Genotype 4 HCV</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>The efficacy of ZEPATIER in subjects with genotype 4 chronic HCV infection was demonstrated in C-EDGE TN, C-EDGE COINFECTION, C-EDGE TE, and C-SCAPE. C-SCAPE was a randomized, open-label trial which included treatment-naïve subjects with genotype 4 infection without cirrhosis. Subjects were randomized in a 1:1 ratio to EBR 50 mg once daily + GZR 100 mg once daily for 12 weeks or EBR 50 mg once daily + GZR 100 mg once daily + RBV for 12 weeks. In these combined studies in subjects with genotype 4 infection, 64% were treatment-naïve; 66% of the subjects were male; 87% were White; 10% were Black or African American; 22% had cirrhosis; and 30% had HCV/HIV-1 co-infection. </p>
                        <p>In C-SCAPE, C-EDGE TN, and C-EDGE COINFECTION trials combined, a total of 66 genotype 4 treatment-naïve subjects received ZEPATIER or EBR + GZR for 12 weeks. In these combined trials, SVR12 among subjects treated with ZEPATIER or EBR + GZR for 12 weeks was 97% (64/66). </p>
                        <p>In C-EDGE TE, a total of 37 genotype 4 treatment-experienced subjects received a 12- or 16-week ZEPATIER with or without RBV regimen. SVR12 among randomized subjects treated with ZEPATIER + RBV for 16 weeks was 100% (8/8). </p>
                     </text></div>
</div>
</div>
<div class="section">
<div id="nonCollapsableElement_34069-5">
<div class="drugSubheadings">
<span id="ZEPATIER_34069-5" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>16 HOW SUPPLIED/STORAGE AND HANDLING</div>
<div id="ZEPATIER_previewText_34069-5" class="previewText">
                  Each ZEPATIER tablet contains 50 mg elbasvir and 100 mg grazo<span>...</span>
</div>
</div>
<div id="ZEPATIER_collapsableElement_34069-5" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText"><text>
                  <p>Each ZEPATIER tablet contains 50 mg elbasvir and 100 mg grazoprevir, is beige, oval-shaped, film-coated, debossed with "770" on one side and plain on the other. The tablets are packaged into a carton (NDC 0006-3074-02) containing two (2) 14-count child-resistant dose packs for a total of 28 tablets.</p>
               </text></div>
<span id="ZEPATIER_collapsableElement_" class="safetySubheading"></span><div id="44425-7" class="safetySubdescription"><text>
                        <p>Store ZEPATIER in the original buler package until use to protect from moisture.</p>
                        <p>Store ZEPATIER at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (between 59°F to 86°F) [see USP Controlled Room Temperature].</p>
                     </text></div>
</div>
</div>
<div class="section">
<div id="nonCollapsableElement_34076-0">
<div class="drugSubheadings">
<span id="ZEPATIER_34076-0" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>17 PATIENT COUNSELING INFORMATION</div>
<div id="ZEPATIER_previewText_34076-0" class="previewText">
                  Advise the patient to read the FDA-approved patient labeling <span>...</span>
</div>
</div>
<div id="ZEPATIER_collapsableElement_34076-0" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText"><text>
                  <p>Advise the patient to read the FDA-approved patient labeling (<a href="#PPI">Patient Information</a>). </p>
                  <p>For patients receiving ZEPATIER with ribavirin, advise patients to read the FDA-approved patient labeling (Medication Guide) for ribavirin <content stylecode="italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</content>.</p>
               </text></div>
<span id="ZEPATIER_collapsableElement_" class="safetySubheading"></span><div id="42229-5" class="safetySubdescription"><text>
                        <p>
                           <content stylecode="underline">Risk of ALT Elevations</content>
                        </p>
                        <p>Inform patients to watch for early warning signs of liver inflammation, such as fatigue, weakness, lack of appetite, nausea and vomiting, as well as later signs such as jaundice and discolored feces, and to consult their healthcare professional without delay if such symptoms occur <content stylecode="italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a> and <a href="#S6.1">Adverse Reactions (6.1)</a>]</content>.</p>
                     </text></div>
<span id="ZEPATIER_collapsableElement_" class="safetySubheading"></span><div id="42229-5" class="safetySubdescription"><text>
                        <p>
                           <content stylecode="underline">Pregnancy</content>
                        </p>
                        <p>Advise patients taking ZEPATIER with ribavirin to avoid pregnancy during treatment and within 6 months of stopping ribavirin and to notify their healthcare provider immediately in the event of a pregnancy <content stylecode="italics">[see <a href="#S8.1">Use in Specific Populations (8.1)</a>]</content>.</p>
                     </text></div>
<span id="ZEPATIER_collapsableElement_" class="safetySubheading"></span><div id="42229-5" class="safetySubdescription"><text>
                        <p>
                           <content stylecode="underline">Drug Interactions</content>
                        </p>
                        <p>Inform patients that ZEPATIER may interact with some drugs; therefore, advise patients to report the use of any prescription, non-prescription medication, or herbal products to their healthcare provider <content stylecode="italics">[see <a href="#S4">Contraindications (4)</a>, <a href="#S5.3">Warnings and Precautions (5.3)</a>, and <a href="#S7">Drug Interactions (7)</a>]</content>.</p>
                     </text></div>
<span id="ZEPATIER_collapsableElement_" class="safetySubheading"></span><div id="42229-5" class="safetySubdescription"><text>
                        <p>
                           <content stylecode="underline">Storage </content>
                        </p>
                        <p>Advise patients to store ZEPATIER in the original package until use to protect from moisture <content stylecode="italics">[see <a href="#S16">How Supplied/Storage and Handling (16)</a>]</content>. </p>
                     </text></div>
<span id="ZEPATIER_collapsableElement_" class="safetySubheading"></span><div id="42229-5" class="safetySubdescription"><text>
                        <p>
                           <content stylecode="underline">Administration</content>
                        </p>
                        <p>Advise patients to take ZEPATIER every day at the regularly scheduled time with or without food. Inform patients that it is important not to miss or skip doses and to take ZEPATIER for the duration that is recommended by the healthcare provider.</p>
                     </text></div>
</div>
</div>
<div class="section"><div id="ZEPATIER_collapsableElement_42229-5" style="margin-left:68px; margin-top: 20px;" class="collapseElement"><div class="descriptionText"><text>
                  <p>Manufactured for: Merck Sharp &amp; Dohme Corp., a subsidiary of<br>
                     <content stylecode="bold">MERCK &amp; CO., INC.,</content> Whitehouse Station, NJ 08889, USA</p>
                  <p>Manufactured by:<br>MSD International GmbH, Ballydine, Clonmel, Ireland</p>
                  <p>For patent information: www.merck.com/product/patent/home.html</p>
                  <p>Copyright © 2016 Merck Sharp &amp; Dohme Corp., a subsidiary of <content stylecode="bold">Merck &amp; Co., Inc.</content>
                     <br>All rights reserved.</p>
                  <p>uspi-mk5172a-t-1601r000</p>
               </text></div></div></div>
<div class="section"></div>
<div class="section"><div id="ZEPATIER_collapsableElement_42229-5" style="margin-left:68px; margin-top: 20px;" class="collapseElement"><div class="descriptionText"><text>
                  <p>Manufactured for: Merck Sharp &amp; Dohme Corp., a subsidiary of<br>
                     <content stylecode="bold">MERCK &amp; CO., INC.,</content> Whitehouse Station, NJ 08889, USA</p>
                  <p>Manufactured by:<br>MSD International GmbH, Ballydine, Clonmel, Ireland<br>For patent information: www.merck.com/product/patent/home.html<br>The trademarks depicted herein are owned by their respective companies.<br>Copyright © 2016 Merck Sharp &amp; Dohme Corp., a subsidiary of <content stylecode="bold">Merck &amp; Co., Inc.</content>
                     <br>All rights reserved.</p>
                  <p>Issued: 1/2016<br>usppi-mk5172a-t-1601r000</p>
               </text></div></div></div>
<div class="section"></div>
</div>